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Thesis Abstract: 
Iron status, its associations and its impact on quality of life, was investigated in a cohort 
of patients residing in Newfoundland & Labrador. The population included individuals 
who were either affected with mild hemophilia A or were carriers of the Val20 16Ala 
allele mutation that underlies the disease. The clinical impact of mild hemophilia A on 
serum ferritin, menstrual blood losses, quality of life and Body Mass Indices (BMis) were 
investigated as part of a 2-year cross-sectional cohort study. The methodology included 
serum ferritin concentrations, complete blood counts (CBCs), the pictorial blood loss 
assessment chart (PBAC), bleeding histories, MOS short-form survey (SF-36) and BMis. 
Iron depletion was prevalent in women (62% with ferritin levels <50 J.Lg/L, 33% <20 
J.Lg/L), particularly in those who were menstruating (80% <50 J.Lg/L, 47% <20 J.Lg/L). 
Women in general self-reported a lower mean General Health Scale score (63.9, 59.9-
67.9 vs. 70.6, 69.5-71.7) and a higher mean Role Emotional Scale score (89.3, 85.8-92.8 
vs. 79.5, 77.7-81.3) than norms for the general U.S. female population. Men with a 
history of severe bleeding had significantly lower ferritin levels than men without a 
history of severe bleeding (123.4 J.Lg/L, 63.6-186.3 vs. 189.8 J.Lg/L, 105.9-301.5; p <0.05). 
Mutation status did not influence iron status in either sex or menstrual blood loss in 
women as measured by the PBAC. Serum ferritin level was not associated with PBAC 
score, but was related to women's BMI (r = 0.235, p <0.01). Neither the means of the 
eight SF-36 domains, health transition scale, nor the two component summary measures 
were significantly lower for mildly iron-deficient or iron-deficient women. The SF-36 is a 
general measure of various quality of life domains and may not have been sensitive 
enough to measure the effects iron deficiency could potentially have on women's 
cognition and fatigue. A study using measures more sensitive to these effects would 
better investigate the impact of iron depletion and iron deficiency. Further research is also 
required to determine whether the low ferritin levels observed in women could possibly 
be a result of inadequate dietary intake of iron or insufficient iron absorption. 
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1.0 Thesis Overview 
This thesis will be presented in six chapters. Chapter 1 gives an overview of the 
chapter contents along with the co-authorship statement. 
The intent of chapter 2 is to provide an overall view of iron deficiency, its 
associations and impacts, and the possible role it may play in individuals with mild 
hemophilia A. Detailed information regarding specific associations and impacts among 
iron-deficient individuals including mutation status, blood loss and cognition and fatigue 
is provided. Moreover, a review of relevant literature regarding prevalence of mild 
hemophilia A and iron deficiency is incorporated. Finally, the rationale for conducting 
this investigation is presented. 
Chapter 3 includes the research questions of our study. The exact testable 
questions consisting of our primary and secondary objectives regarding our investigation 
is specified. 
Chapter 4 includes our methods which discusses the study design, population, 
patient recruitment and assessment. To finish, a discussion of our outcomes, statistical 
analysis, data management and ethical considerations is presented. 
In chapter 5, the baseline description of our subjects is provided. The results of 
the analysis of both the primary and secondary outcomes along with level of statistical 
relevance are offered. 
And finally, in chapter 6, our discussion and implications of our results in terms 
of our outcomes are presented. Conclusions that may be reasonably drawn form the. 
outcomes of the study along with associated strengths and weaknesses are provided. 
Direction for future studies is also included. 
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2.0 Overview 
Initially, as part of a two-year cross-sectional cohort study aimed at defining the 
clinical impact of mild hemophilia A, a kindred with the same Factor VIII mutation 
underlying the disease who predominantly resides in the province of Newfoundland and 
Labrador, Canada was identified. Many adult women enrolled were subsequently 
identified as having low iron stores and literature suggests that iron depletion can have a 
significant effect on cognition and fatigue. This thesis is specifically focused on the 
burden of sub-optimal iron status in a population including this kindred of patients and its 
associations. 
While there is little evidence to suggest that iron deficiency may be a 
complication in males, there is reason to believe that female carriers of mild hemophilia 
A could be at risk for having low iron stores (Kadir, Economides, Sabin, Pollard, & Lee, 
1999). In general, mild hereditary b leeding disorders c an have a significant impact on 
women - namely, prolonged and heavy menstrual bleeding - and signs of iron deficiency 
are commonly present in women who experience more than 60 ml of blood loss per 
month. Studies of iron status among adult women in Canada are also greatly lacking and 
are essentially non-existent for women in Newfoundland and Labrador. In recognition of 
this need, we are documenting the prevalence of iron deficiency and iron depletion in a 
rural population including affected men and women who are symptomatic and 
asymptomatic obligate carriers of the Val2016Ala allele mutation that underlies mild 
hemophilia A. We are also investigating the association of iron status with blood loss and 
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other potentially influential variables, and the potential impact sub-optimal iron status 
may have on various quality of life parameters. 
2.1 Mild Hemophilia A 
2.1.1 Background 
Hemophilia is the second most common hereditary bleeding disorder in the world 
after von Willebrand's disease (vWD). Hemophilia A and B are sex-linked recessive 
disorders with defining phenotypes of cofactor VIII and IX deficiencies, respectively. 
The severity of bleeding is generally accepted to correlate with the level of factor activity 
and depending in part on the genetic mutation, the level of factor VIII activity can vary. 
According to the International Society on Thrombosis and Haemostasis (ISTH) standards, 
severe hemophilia is defined by factor levels less than 1% (0.01 U/mL), moderately 
severe hemophilia is diagnosed if the diagnostic factor levels are between 1 and 5% (0.01 
to 0.05 U/mL) and mild hemophilia is characterized by a factor activity between 5 and 
40% (0.05 to 0.40 U/mL) (White, Rosendaal, Aledort, Lusher, Rothschild, & Ingerslev, 
2001). 
Determining, with precision, the true global prevalence of mild hemophilia A to 
use as a reference standard is difficult. The observed prevalence of hemophilia is 
dependent on the incidence at birth and the duration or mortality of the diseases, both of 
which have changed, and will continue to change, as a result of improved screening 
procedures and treatment, respectively. The prevalence of co-morbid conditions such as 
HIV/AIDS and Hepatitis C, as well as the availability of screening procedures and 
treatment, also differ from one country to another, affecting national mortalities and the 
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ensuing national prevalence. Considering these limitations, the overall prevalence of 
hemophilia A in many Western countries is estimated to be around 1 in 5,000 (Rosendaal 
& Briet, 1990). 
2.1.2 Mild Hemophilia A in Newfoundland 
The number of people registered with hemophilia A in Canada is approximately 1 
m 10,000 (Canadian Hemophilia Registry, 2004) and exclusively in the province of 
Newfoundland & Labrador 1 in 5000 persons are registered as having hemophilia A 
(Newfoundland and Labrador Hemophilia Registry, personal communication, December, 
2004). What is strikingly different in the province of Newfoundland & Labrador is the 
unusually high proportion of mild cases of hemophilia A as determined by Factor VIII 
activity levels. While the most recent comprehensive national audit, performed by the 
Canadian Hemophilia Registry during March to July 2004, reports 1330 of2221 (59.9%) 
factor VIII hemophiliacs as mild, in the province of Newfoundland and Labrador the 
prevalence is much higher with 104 of 114 (91.2%) registered patients with hemophila A 
being classified as mild. Eleven of the 104 registered patients are female with factor VIII 
levels less than 30% and are considered to have mild hemophilia rather than just simply 
being labelled as "carriers" (Newfoundland and Labrador Hemophilia Registry, personal 
communication, December, 2004). 
This unusual pattern of disease is likely a result of a founder effect. Dr. Yagang 
Xie's laboratory at Memorial University of Newfoundland working in collaboration with 
Dr. David Lillicrap's laboratory at Queen's University and Dr. R. Bagnell's laboratory at 
King's and St. Thomas' Medical School in England have identified a single nucleotide 
16 
polymorphism in the factor VIII genes, resulting in an amino acid change from valine 
(GTG) 2016 to alanine (GCG), as the underlying defect in this kindred. All affected 
males and obligate female carriers in the population carried the same mutant allele. This 
factor VIII mutation was found to be a molecular event independent o fa V al20 16Ala 
mutation localized in South East England via the identification of distinct factor VIII 
polymorphic haplotypes between the Newfoundland and English populations (Xie, 2002). 
The initial small population size, minimal immigration, and stagnated population growth 
in the New World Island region of Newfoundland and Labrador, likely facilitated the 
enrichment of the Val2016Ala allele. 
2.1.3 Burden of Mild Hemophilia A 
Although mild hemophilia has been reported in the literature since 1953, there is a 
paucity of studies with adequate power in the literature addressing bleeding in mild 
hemophiliacs. The largest cohort study includes 55 patients and is confined to patients 
aged less than 17 years of age. Bleeding episodes extracted from medical records mostly 
occurred in muscle/soft tissue or joints and were associated with trauma (Venkateswaran, 
Wilimas, Jones, & Nuss, 1998). Anecdotal evidence from small case series also suggest 
that patients with mild hemophilia, although they do not tend to bleed spontaneously, can 
have the same spectrum of significant bleeding disorders as patients with moderate and 
severe hemophilia if they experience trauma or surgery (Pappas, Salzman, Britten, & 
Riseborou, 1964; Coy, Bivins, & Belin, 1974; Beall, O'Leary, & Pierce, 1974). A number 
of case reports in the literature have used the term occult hemophilia to refer to mild 
hemophilia A and B (Aggeler, Hoag, Wallerstein, & Whissell, 1961; Kitchens, 1980). It 
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1s generally felt that in these disorders, bleeding is less severe, does not occur 
spontaneously, and only occurs in response to trauma or surgery. However, no published 
cohort studies assessing long term musculoskeletal complications in middle and late 
adulthood of patients diagnosed with mild hemophilia A were found. 
Preliminary clinical evaluation of a large cohort of patients with mild hemophilia 
A in the province of Newfoundland and Labrador has shown that the diagnosis is often 
delayed and certainly some patients in this cohort appear to have experienced significant 
musculoskeletal problems potentially related to undiagnosed hemophilia A. Ideally 
patients diagnosed with mild hemophilia A should undergo a response trial of 
Desmopressin (DDA VP). Patients who do respond well should receive early treatment 
with DDA VP for mild to moderate musculoskeletal injury and receive infusions with 
Recombinant Factor Vill for more severe injury. 
In patients with severe hemophilia A, the most likely cause of death prior to 
contamination of the blood supply with the HN and hepatitis C virus was bleeding into 
the central nervous system (Andes, Wulff, & Smith, 1984; Eyster, Gill, Blatt, Hilgartner, 
Ballard, Kinney, 1 978). Whether or not intracranial bleeding is an important issue for 
patients with mild hemophilia A has not been well documented. Another important type 
of bleeding in severe hemophilia is spontaneous gross hematuria, which is generally a 
painless benign condition unless accompanied by large clot formation. An increased 
prevalence of hypertension has also been reported in this patient population (Rosendaal et 
al., 1990). The prevalence of these disorders in patients with mild hemophilia A is 
currently unknown as is the prevalence of other problems such as epistaxis, 
gastrointestinal bleeding and bleeding with dental work. 
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2.1.4 Iron Deficiency in Male Hemophiliacs 
Iron deficiency is generally not considered a complication of hemophilia in men 
despite it commonly being a result of the occult or overt blood losses previously 
mentioned. The literature exploring the state of iron balance in male hemophiliacs is 
sparse, although one small case series questioned whether intermittent occult blood loss 
from microscopic subclinical hematuria might predispose moderate to severe 
hemophiliacs to iron deficiency. L ottenberg et a l. examined bone marrow hemosiderin 
levels, radioactive iron kinetics, serum ferritin measurement, serum iron, and iron-
binding capacity, seeking to measure urinary and stool blood loss in 8 male hemophiliacs. 
All the patients had factor levels in either the moderate (n=1) or severe range (n=7) as 
according to ISTH standards, with one patient having severe factor IX deficiency and the 
remainder having factor Vill deficiency. Patients with active genitourinary bleeding were 
excluded. The authors did not observe any overt bleeding episodes and found it difficult 
to persuade some subjects to return for follow-up observations. Four of the hemophiliac 
bone marrow hemosiderin estimates had no visible iron and the differences between age-
matched, non-anemic, Hodgkin's or non-Hodgkin's lymphoma (stage I or IIA) controls 
and hemophiliac samples was significant (p<0.001) (Lottenberg, Kitchens, Roessler, & 
Noyes, 1981). 
The authors state that serum iron values, percent saturation, and serum ferritin 
levels were not suggestive of iron deficiency and suggest that inc ombination with an 
observed decline in total-body radioactive iron, this evidence is consistent with normal 
body iron balance. Lottenberg et al. suggest 2 hypothesises for what they consider a 
discrepancy between the bone marrow samples and the other measures of iron status: (i) 
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the external blood loss that went undetected must have been minimal or (ii) the external 
blood loss was insignificant, but as internal tissue bleeding occurs, iron is subsequently 
deposited in hemosiderin-laden macrophages in synovia and other connective tissue and 
is not redistributed to the marrow, reducing bone marrow stores, but leaving ferritin 
levels and therefore erthropoiesis maintained. However, the authors used a serum ferritin 
cut-off of< 12 !J.g/L as indicative of iron deficiency and literature suggests that this cut-
off is low and may exclude patients who have adverse health consequences associated 
with higher serum ferritin measures. One extensive diagnostic review suggested a cut-off 
of< 40 !J.g/L as optimal (Guyatt, Oxman, Ali, Willan, Mcilroy, & Patterson, 1992). The 4 
patients with bone marrow hemosiderin samples showing no visible iron. had serum 
ferritin values of 12, 18, 40 and 66 !J.g/L (Lottenberg, Kitchens, Roessler, & Noyes, 
1981). Taken together, this weakens the validity of the author's implication that there is a 
discrepancy between these measures and the conclusion that all the patients had normal 
body iron stores. 
One other study systematically evaluated anem1a and iron status in a large 
population of children and young adult men with hemophilia. In this cross-sectional 
cohort study 94 boys (n=74) or young men (n=20) were prospectively evaluated during 
routine comprehensive hemophilia clinic visits. As per ISTH standards, 49 were severe, 
28 moderate, and 17 mild. Seventy-eight patients were factor VIII deficient, 14 factor IX 
deficient, and 2 had another deficiency. Thirty-four were HN positive and none of the 
patients were receiving iron supplementation at the time of the study. Slightly reduced 
hemoglobin values, expressed as age-related percentiles, were observed in hemophiliacs 
of all ages. Twenty-nine of the patients (31 %) were considered frankly anemic with 
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values less than the third percentile for age. While none of the adult patients had frank 
anemia, 75% of them had hemoglobin values less than the mean value for age. The 
mechanism of the reduced hemoglobin in the entire study population or in individual 
patients with the lowest hemoglobin values was not clear and mild sub-clinical iron 
deficiency o r the anemia o f chronic disease w ere not p raven to b e p art o f the anemic 
pathophysiology. Only 5 patients had serum ferritin values < 20 J.Lg/L. The authors 
concluded that slightly decreased hemoglobin values are common in patients with 
hemophilia, but the mechanism of hemoglobin reduction does not appear to be iron 
deficiency or impaired iron reutilization (Buchanan & Holtkamp, 1988). 
The paucity of literature that has evaluated iron status in male hemophiliacs 
suggests that iron deficiency is likely not a complication of the disease. Furthermore, only 
a few of the hemophiliacs in these studies were of mild severity. Therefore, in the present 
study, it is not expected that the prevalence of iron deficiency in males with mild 
hemophilia will be significantly different from normal males. However, given the scarcity 
oft he 1 iterature on this topic these groups will still be compared. While there is 1 ittle 
evidence to suggest that iron deficiency may be a complication in males, there is reason 
to believe that female carriers of mild hemophilia A may be at risk of being iron deficient 
(Kadir et al., 1999). 
2.2 Hemophilia in Women 
2.2.1 Background 
Due to its X-linked inheritance pattern, hemophilia occurs rarely in females. 
However, case-reports have suggested that severely affected girls and women suffer from 
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the same bleeding problems as their male counter-parts and also experience very severe, 
sometimes life-threatening menorrhagia (Lusher & McMillian, 1978; Ulutin, Muftuoglu, 
& Palamar, 1965 Joist, Bouhasin, & Roodman, 1977; Merskey, 1951; De La Chappelle, 
Ikkala, & Nevanlinna, 1961). Wahlberg et al. studied a group of carriers and non-carriers 
of hemophilia A with family histories of both the severe and moderate phenotypes. 
Through combining information from pedigree data and discriminant analysis data, 4 3 
possible carriers were classified as either carriers or non-carriers with about 95% 
confidence. The median (range) factor VIII activity (one-stage assay), expressed as 
percentage of normal pooled plasma, of all carriers (n=38) (obligate and classified 
combined) and those classified as non-carriers (n=16) was 62(25-120) and 88(38-124), 
respectively (p<0.001). The carrier group also had significantly more bleeding symptoms 
than non-carriers (p<0.001) (Wahlberg, Blomback, & Brodin, 1982). 
It has been suggested more recently that mild hemophilia may be more common 
in females than was once originally thought (Venkateswaran, Wilimas, Jones, & Nuss, 
1998). Eyster et al. studied two unrelated families with mild hemophilia A and identified 
6 obligate carriers with low factor VIII procoagulant activity. Both families had 
successive generations of males affected with mild hemophilia A with factor VIII 
procoagulant activities ranging from 0.11-0.18 U/ml in the first family and 0.059-0.10 
U/ml in the other. The factor VIII procoagulant values of 2 of the 5 carriers in the first 
family was 0.41 and 0.59 and the values in 4 of the 6 carriers in the other family was 
0.36, 0.35, 0.20, and 0.23 U/ml. Based on their findings the authors emphasize that factor 
VIII levels should be determined on all obligate or suspected carriers prior to surgery or 
·' 
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dental extractions so as to identify individuals at risk for postoperative bleeding (Eyster, 
Ladda, & Bowman, 1977). 
2.2.2 Prevalence of mild bleeding disorders 
In general, mild hereditary bleeding disorders can have a significant impact on 
women; namely, prolonged and heavy menstrual bleeding (Kadir, Economides, Sabin, 
Owens, & Lee, 1998; Kadir et al. 1999). Kadir et al. demonstrated that when 150 women, 
referred for menorrhagia assessment, were carefully screened, 17% were diagnosed with 
a congenital bleeding disorder (Kadir et al., 1998). Similarly, using a pictorial blood loss 
assessment chart (PBAC), to assess menstrual blood loss in women with bleeding 
disorders, menorrhagia (PBAC score > 100) was putatively confirmed in patients with 
von Willebrand's disease (vWD), hemophilia carriers, and factor XI deficiency, with a 
prevalence of 73%, 57%, and 59%, respectively. In comparison, menorrhagia was 
confirmed in only 29% of women in the control group (p=0.001). There was no 
difference in the PBAC scores of hemophilia carriers with FXI or FVIII levels ~3.0 
IU/ml compared to those with higher levels, however the number of women with levels 
~3.0 IU/ml who had completed PBAC were very small. Also, while the authors 
demonstrate that a significant number of carriers of hemophilia A or B have verified 
menorrhagia, they caution that the response rate was particular low in this group (26%), 
possibly due to the fact that they suffer less problems compared to the other groups that 
demonstrated higher response rates (vWD, 69%; FXI, 47%; Control, 60%). The findings 
may therefore represent an overestimate because the large number of non-responders 
might have had normal menstruation (Kadir et al., 1999). 
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2.2.3 Menstrual Blood Loss 
These publications by Kadir et al. have generated a global interest in the issue of 
women with menorrhagia and bleeding disorders. Menorrhagia is the term used to 
describe excessive menstrual bleeding. Metrorrhagia is the term used to describe 
menstrual bleeding lasting longer than 7 days of interval bleeding and is another common 
symptom in women with congenital bleeding disorders. A normal cycle will last less than 
7 days and occurs regularly at intervals between 21 and 37 days. Regardless of the length 
of flow, 70% of blood loss will occur by the second day and 90% by the third day. Total 
blood loss of 20-80mL, representing 10-35mg of iron is considered to be normal. The 
mean menstrual blood loss for a normal period is approximately 40mL. Signs of iron 
deficiency are present in a significant proportion of women who lose more than 60mL of 
blood with each menstrual flow (Swartz & Butler, 1992). In a large population study 
Hallberg and associates attempted to define the upper normal limit of the menstrual blood 
loss. Using the accurate and reliable alkaline hematin method to measure menstrual 
losses, and various parameters reflecting the iron state of the body, Hallberg et al. 
showed that signs of iron deficiency are present in women who experience more than 60 
ml ofblood loss and occurs in 67% of women whose menstrual exceeds 80 ml. Based on 
these findings, the upper normal limit of the menstrual blood loss is situated between 60-
80 ml and blood loss above 80 ml is regarded as pathological (Hallberg, Hogdahl, & 
Nilsson, 1966). 
The combination of menorrhagia and metrorrhagia can occur and is particularly 
problematic. Therapeutic interventions such as dilatation and curettage will often worsen 
the problem since scraping the lining of the uterus disrupts any platelet plugs or fibrin 
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clots that may be in place (Paper, 2000). In addition, it is increasingly recognized that 
women with hereditary bleeding disorders that are mild may suffer from dysmenorrhea 
and mid-cycle pain. They may also have problems with conception, fertility and have an 
increased prevalence of post partum hemorrhage (Aledort, 2000; Seeler, 1999). 
Discovering they are obligate carriers may also potentially have a negative psychological 
effect on women and there is a need to properly describe and quantify the potential 
impact of a mild bleeding disorder on their quality of life (Kadir, Sabin, Goldman, 
Pollard, Economides, & Lee, 2000; Ranta, Lehesjoki, Peippo, & Kaariainen, 1994; 
V arekamp, Suurmeijer, Brocker-Vriends, van Dijck, Smit, Rosendaal, & Briet, 1990). In 
this study we are interested in documenting the prevalence of iron deficiency, its 
association with menstrual blood loss, contraceptive usage and body mass index (BMI), 
and the impact it may potentially have on various quality of life parameters, in a 
population including women who are symptomatic and asymptomatic obligate carriers of 
the Val20 16Ala allele mutation that underlies mild hemophilia A. 
2.3 Iron Deficiency in Women 
2.3.1 Iron Compartments, Transport and Depletion Levels 
Measures of iron status reflect changes in different body iron compartments and 
are affected at different levels of iron depletion. Therefore a brief overview of body iron 
compartments, iron transport and distinctions between different 1 evels o f depletion are 
necessary. This is not only essential in order to define different iron deficient states and 
the associated clinical impacts, but to also conceptualize each laboratory measure in 
terms of iron status. 
25 
Iron status can be characterized in relation to the amount of iron held in the 
storage and functional areas of the body. The former is located primarily in the 
parenchymal cells of the liver and the reticulorendothelial cells of the bone marrow, liver, 
and spleen and the latter exists mainly as hemoglobin in red blood cells, and to a lesser 
degree in myoglobin and various tissue enzymes (Cook & Skikne, 1989). Transferrin is 
an iron transport protein that supplies tissues with iron. Transferrin receptors are 
expressed on the surface of cells that require iron and are responsible for internalisation 
of transferrin-bound iron and its intracellular release. The number of membrane receptors 
is proportionate to the number of receptors found in the plasma. Measurements of 
circulating soluble transferring receptors can therefore be used as an indicator of the rate 
of erythropoesis and as an indicator of iron deficiency. Ferritin, another iron-binding 
protein, transports iron from iron stores to functional sites. When iron depletion begins; 
that is, when stores start to decrease due to inadequate supply, there is no dysfunction. 
However, when iron stores are completely empty, or possibly merely considerably 
depleted (iron depletion), this continual imbalance will result in an inadequate iron supply 
to the red cell producing marrow and to tissues for normal biochemistry and function. At 
this point, abnormalities in physiological functions can occur. Small functional deficits 
have been related to reduced memory/attention, increased fatigue, and possibly causing 
excess menstrual bleeding in women (Bruner, Joffe, Duggan, Casella, & Brandt, 1996); 
Verdon et al., 2003; Taymor, Sturgis, & Yahia, 1964). Iron-deficiency is defined as the 
point at which iron stores are completely depleted and is most commonly reflected by 
measuring serum ferritin concentration. The greater the severity and duration of iron 
deficiency, the higher the probability that the iron deficiency may significantly change 
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other laboratory measures such as hemoglobin, transferrin saturation, red cell 
protoporphyrin (RCP), and red cell indices - mean cell volume (MCV) and red cell 
distribution width (RDW). Iron deficient erythropoiesis therefore starts as soon as iron 
stores are depleted, but our ability to detect it depends on methods and cut-offs selected. 
As a result, this classification is vague and the boundary line between erythropoiesis and 
iron deficiency is not stable (Hallberg & Rossander-Hulten, 1991). Iron deficiency 
anemia occurs when there is inadequate iron available to the extent that the amount of 
functional hemoglobin is decreased below a defining level. In the present study, we will 
define the different levels of iron status using serum ferritin concentration, red cell 
indices, and hemoglobin. However, the distinction between depleted iron stores without 
anemia and depleted iron stores with anemia is o f primary interest, and the other iron 
status sublevels should be used only as a conceptual guide. In the absence of a definitive 
quantitative relationship between serum ferritin measures and clinical symptoms in mild 
cases of iron depletion, iron depletion will be treated as a grey-zone with various cut-off 
values (Table 1). An overview of the literature with respect to the utility of using serum 
ferritin as the sole measure of iron status (without MCV, RDW, etc.), the various serum 
ferritin cut-off values, and the differences between the cut-off values for men and women 
are discussed in the methods chapter. 
27 
Table 1.1: Laboratory definitions of sub-optimal iron status for females and males 
Sub-optimal Iron Status Laboratory Definition 
Sex Serum Ferritin MCV(fL) RDW Hemoglobin ()lg/L) (Units) (giL) 
Iron depletion F <50, 40, or 20 Normal Normal Normal M <50,40,or30 
Iron Deficiency F <11 Normal Normal Normal M <24 
Iron Deficient Erythropoiesis F <11 <80 >14.5 Normal M <24 
Iron Deficiency Anemia F <11 <80 >14.5 <120 M <24 <140 
* Iron depletion IS not well defined and will be treated as a grey-zone with vanous cut-off 
values 
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2.3.2 Prevalence of Iron Deficiency 
Iron deficiency is far less prevalent in developed countries than in undeveloped 
countries. How ever, while significant progress has been made over the I ast century in 
combating iron deficiency in many industrialized countries, iron deficiency still remains a 
public health concern for selected subgroups. Women ofreproductive age with excess 
menstrual blood losses and pregnant women who cannot meet requirements from their 
diet alone are at risk and iron deficiency still remains the most common nutritional 
deficiency among 15-49 year old women in the western world (Ramakrishnan, & Yip, 
2002; Ferguson et al., 2001). 
Depending on the laboratory criteria, methodology, epidemiologic factors (co-
morbid conditions, age, contraception), and nutrition factors (heme and non-heme iron 
intake, vitamin C, iron supplementation), the prevalence of sub-optimal iron status will 
vary. Prevalence measures primarily using serum ferritin will be noted because it shows 
the least overlap between iron replete and iron deficient states (Guyatt et al., 1992; 
Hallberg, Bengtsson, Lapidus, Lindstedt, Lundberg, & Hulten, 1993). From a random 
sample of adults aged 25-65 years in the capital area of Finland, iron status was evaluated 
via serum ferritin in 137 non-pregnant women. In women aged 25-50 years, 20% had 
serum ferritin results <12J.Lg/L and 32% <16J.Lg/L (mean± SD = 32 ± 12)lg/L; n=84). In 
contrast, women aged 51-65 years had corresponding serum ferritin results of 11% and 
13% (mean± SD = 62 ± 59)lg/L; n=53) (Lahti-Koski, Valsta, Alfthan, Tapanainen, & 
Aro, 2003). In Norway, iron deficiency defined as ferritin <17J.Lg/L was observed in 
21.8% (mean± SD = 34.1 ± 23.9; n=147) of menstruating, non-pregnant, women aged 
18-48 years who were non-blood-donors, aged 18-48 years (Borch-Iohnsen, Meltzer, 
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Stenberg, & R einskou, 1 989). In contrast, iron deficiency as defined by serum ferritin 
<16J.tg/L was observed in 9.7% of 268 menstruating, non-pregnant Danish women 18-30 
years of age (Milman, Clausen, & Byg, 1998). In the Netherlands 16% of 75 non-
pregnant women aged 20-49 had low iron stores (serum ferritin <10J.tg/L) (Brussaard, 
Brants, Bouman, & Lowik, 1997). 
In The Dietary and Nutritional Survey of British Adults (1990) 17% of 520 
menstruating women aged 18-49 had serum ferritin scores <13J.tg/L (Hallberg, 1995); in 
the area of Coleraine, Northern Ireland, 18.2 %of 192 women aged 18-44 had serum 
ferritin scores <12J.tg/L (Strain, Thompson, Barker, & Carville, 1990); and in Dublin, 
36% and 45% of 106 women aged 16-25 had scores <12J.tg/L and <l5J.tg/L, respectively 
(Wickham, Broin, O'Rourke, Condren, Scott, & Kevany, 1985). The overall prevalence 
of sub-optimal iron status among 15-49 year old women in New Zealand (n=1751) was 
also shown to range from 7 (<12J.tg/L) to 13% (<l6J.tg/L) (Ferguson et al., 2001). In 
summary, for populations of non-pregnant, menstruating women, varying in age from 15-
50 years, which reside in either northern I central Europe or New Zealand, the prevalence 
of sub-optimal iron status ranges from 7-45%, as defined by serum ferritin cut-offs 
ranging from 10-20 J.tg/L. 
The National Health and Nutrition Examination Surveys (NHANES III, 1988-
1994 and NHANES 1999-2000) conducted in the United States used more stringent 
criteria for iron deficiency; that is, the definition of iron deficiency was based on 3 
laboratory tests of iron status - free erythrocyte protoprophyrin, transferrin saturation, 
and serum ferritin - rather than serum ferritin alone. To be considered iron deficient, 
individuals had to have abnormal values for two or more measures of iron status. 
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NHANES III showed that for non-pregnant women aged 20-49 (n=4495), 11% were 
found to be iron deficient with either 2 of the following 3 results: transferrin saturation 
< 15%, serum ferritin < l2J..1.giL, or erythrocyte protoporphyrin > 1.24 J.lmol/L RBCs 
(Looker, Dallman, Carroll, Gunter, & Johnson, 1997). Similarly, using the same criteria, 
NHANES 1999-2000 indicated that 12% of non-pregnant women aged 20-49 (n=949) 
were iron deficient (CDC, 2002). 
In contrast to Europe, and possibly the United States, measurements of iron status 
for adult Canadian women are sparse. Using data from the Nutrition Canada Survey 
(1973) designed to sample the population in five regions (Atlantic, Quebec, Ontario, 
Prairies, and British Columbia), V alberg et al. found 27% of non-pregnant women aged 
20-39 (n=lOO) and 24% of non-pregnant women aged 40-64 (n=l05) had serum ferritin 
results <l5J..1.g/L (Valberg, Sorbie, Ludwig, & Pelletier, 1976). To our knowledge, the 
only other study of iron status in Canadian women was conducted by Newhouse et al. in 
Thunder Bay, Ontario. Iron depletion measured by serum ferritin levels <20J.lg/L was 
identified in 39% of Ill women aged 18-40 (Newhouse, Clement, & Lai, 1993). In a 1 
day recall study, Troppman et al. found that only about 15% of men and 19% of women 
used iron containing (multivitamin supplements while less than 2% of contacted persons 
used a pure iron preparation (Troppmann, Gray-Donald, Johns, 2002). 
Community studies of iron status for women in Canada are somewhat lacking and 
are essentially non-existent for women in Newfoundland and Labrador. While there are 
no recent studies showing the body iron status of individuals in Newfoundland and 
Labrador, Nutrition Newfoundland and Labrador: The Report of a Survey of Residents of 
Newfoundland and Labrador, 1996, suggested that although the iron intakes of males and 
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semor females appeared adequate, many females less than 50 years appeared to be 
consuming an inadequate amount of iron. Inadequate intake was calculated using the 
Estimated Average Requirement (EAR) method according to the Full Probability 
approach. The calculation accounted for the asymmetry in iron requirements over the 
population as a result of menstruating women, and allowed for the consideration of some 
uncertainty factors in the estimation (oral contraception use and sampling distribution). 
The survey showed that 25.3% of females aged 19-30 and 33.3% of females aged 31-49 
were consuming <EAR (Roebothan, 2003). In the present study we measured iron status, 
and calculated the prevalence of the different levels of suboptimal iron status, for women 
and men living in rural Newfoundland and Labrador. 
2.3.3 Blood Loss and the Etiology of Iron Deficiency 
There are numerous factors that appear to influence iron status and that may make 
women susceptible to iron depletion, iron deficiency, developing subsequent iron-
deficient erythropoiesis, or anemia. A few potentially modifiable factors are menstrual 
losses, nutrition, iron absorption and BMI. 
Since blood is rich in heme-iron, excessive blood loss can lead to iron-deficiency 
and possibly anemia. Women presenting with menorrhagia are at risk of becoming iron-
deficient and may require nutritional supplementation. Signs of iron deficiency are 
present in women who experience more than 60 ml of blood loss and occur in 67% of 
women whose menstrual losses exceed 80 ml (Hallberg et al., 1966). It has also been 
suggested that iron deficiency itself can lead to or aggravate the menstrual blood loss; 
that is, the coagulative capacity of the uterus may be reduced, creating a cycle of more 
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blood loss, and consequently more iron loss. A double-blind placebo controlled trial 
found that supplementing with iron decreases excess menstrual blood loss in iron-
deficient women who had no underlying cause for their condition (Taymor et al., 1964 ). 
However the validity of these results are in question, considering that the methodology 
used, by present day standards, was weak; that is, no objective assessment of menstrual 
blood loss was used and serum iron levels, which may not always accurately reflect the 
status oftissue iron in the body, were used to measure iron status. 
Iron status has been shown to be significantly less in pre-menopausal than in post-
menopausal women. Milman et al. compared iron status in relation to menstruation in pre 
and post-menopausal Danish women aged 35-65. Menopausal status was determined 
from the detailed medical history given by the participants. Pre-menopausal women 
(n=676) had lower serum ferritin scores, median 42 J.lg/1, than post-menopausal women 
(n=207), median 80 J.lg/L (p<O.OOOl). Of the pre-menopausal women, 12.1% had serum 
ferritin scores <20 J.lg/L and 47.6% had scores <40 J.lg/1. The corresponding percentages 
in post-menopausal were 0.5% and 13.5%. Serum ferritin levels in pre-menopausal 
women were strongly dependent on the duration of menstrual bleeding (p<O.OOOl), which 
was in turn related to the method of contraception (Milman, Rosdahl, Lyhne, J0rgensen, 
& Graudal, 1993). A national sample of adults aged 35-60 years living in France also 
showed that post-menopausal women (n=1706) had a higher mean serum ferritin level 
than pre-menopausal women (n=4942) (71.3 J.tg/L vs. 33.6 J.lg/1, p<O.OOl) and pre-
menopausal women had a higher prevalence of iron deficiency (serum ferritin <15 J.tg/L) 
than post-menopausal women and men (n-2337) (22.7 vs. 5.3% vs. 1.8%, p<O.OOI). 
(Galan et al., 1998). 
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Blood loss and diet play a role in the etiology of iron depletion. In a cross-
sectional study of a volunteer sample of 384 pre-menopausal women, women aged 18-40 
years were chosen to maximise the likelihood that all reached menarche and had finished 
growing and to minimise the likelihood that they had reached menopause. The 87 (23%) 
women with iron depletion (serum ferritin <20 f.!.g/L; hemoglobin> 120 giL), termed as 
mild iron deficiency by the authors, had significantly lower BMI (21.8; SD = 20.4, 
interquartile range= 24.5) than the 297 women without iron depletion (23.0; SD = 21.1, 
interquartile range= 25.1) {p=0.01) and significantly lower intake of meat/fish/poultry 
(86g vs. lllg) (p<0.01). Menstrual blood loss, as determined by a menstrual recall 
method, was not significantly different between the two groups (Heath, Skeaff, Williams, 
& Gibson, 2001 ). 
Logistic regression analysis suggested that meat/fish/poultry intake and menstrual 
blood loss were important predictors of mild iron deficiency, when adjusting for other 
independent risk factors. Consuming medium or high intakes of meat/fish/poultry was 
associated with a decreased risk of iron depletion in women who experienced low 
menstrual losses (Odds Ratio (OR) = 0.22, 95% CI = 0.09-0.56 and OR= 0.26, 95% CI = 
0.10-0.67, respectively) and experiencing low menstrual losses was also associated with a 
decreased risk in women consuming a medium amount of meat/fish/poultry (OR= 0.13, 
95% CI = 0.03-0.59). Independent risk factors that were significantly important 
predictors included: duration of menstrual period <4 days (OR = 0.35, 95% CI = 0.16-
0.77), <4 months since last blood donation (OR = 7.27, 95% CI = 2.79-18.92), nose 
bleeds (yes) (OR= 2.15, 95% CI = 1.12-4.11), BMI <20 (OR= 2.50, 95% CI = 1.14-
5.50), and multivitamin-mineral supplementation in the past year (yes) (OR= 0.48, 95% 
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CI = 0.24-0.98). The authors demonstrated that the risk of iron depletion in pre-
menopausal New Zealand women is associated with blood loss; namely, menstrual blood 
loss, recent blood donation and nosebleeds, and is also associated with intake of 
meat/fish/poultry. Women with low menstrual losses may be able to lower their risk for 
iron depletion by increasing there intake of heme-iron and those with a medium intake of 
meat/fish/poultry may benefit from taking steps to decrease their menstrual losses. They 
also suggest that women with a low BMI should strive to reach the healthy range (Heath 
et al., 2001). 
Moderate daily doses of ferrous iron supplementation appear to influence the iron 
status of women with inadequate iron stores. Iron deficiency, as defined by serum ferritin 
<16J.Lg/L, was observed in 9.7% of268 menstruating, non-pregnant Danish women 18-30 
years of age, whereas the prevalence o firon deficiency was 4.3% in users (n=94) v s. 
12.6% in non-users (n=174) when consumption of iron supplements was considered 
(p=0.05) (Milman et al., 1998). Milman et al. did not measure menstrual blood loss, but 
they did show that in non-iron-supplemented women, serum ferritin levels were inversely 
correlated with the duration of menstrual bleeding (r = -0.25, p<0.001) and with self-
assessment of intensity of menstrual bleeding (r = -0.27, p<0.001). No correlation was 
observed in iron supplemented women. 
While it is well accepted that excessive menstrual blood loss leads to iron 
deficiency, the amount of menstrual losses experienced by women can also be highly 
variable. Consequently, variables that influence menstrual losses may influence iron 
status. Contraception, age and parity, and baby weight have all been suggested to be 
associated with menstrual losses (Cole, Bilewicz, & Thomson, 1971). Cole et al. (1971) 
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measured menstrual blood losses, via the most accurate and reliable alkaline hematin 
method, in 348 women aged 17 to 45 years in a Northumbrian mining village. Menstrual 
loss was found to be related to whether oral contraception (mean losses = 12.7 ml, sd = 
20.4, n=23), an intrauterine device (mean losses = 56.3 ml, sd = 35.2, n=25) or no 
contraception (mean losses = 37.9, n=280) was used (p<O.OOl); parity independent of 
contraception (r= 0.19, p<O.Ol, n=280) and within parity groups, to the average birth 
weight of previous children (r = 0.28, p<O.Ol), but not age. The authors also suggested 
that menstrual losses, excluding the influence of parity, may be associated with height 
(rpartial = 0.19, p<O.Ol), although when birth weight of previous child is taken into account 
the correlation fails to reach significance. Endometrial area or vascularity may explain 
this relationship as taller and heavier women tend to have heavier babies and may have 
larger uteri. Weight was also correlated with menstrual losses, but not independent of 
parity and age as body weight tends to change with these variables (Cole et al., 1971). In 
another study designed to isolate epidemiological risk factors for menorrhagia, menstrual 
blood loss during one bleeding episode for each of 182 women was measured with the 
alkaline hematin method. Menstrual blood loss increased significantly with age (p<0.03) 
and the percentage of women with menorrhagia was significantly higher above 40 years 
of age (p<O.OS). BMI was found not to be significantly related to menorrhagia nor was 
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parity after adjustment for age (Janseen, Scholten, & Heintz, 1997). Similarly, Deeny et 
al measured menstrual blood loss in 54 women, referred for endometrial ablation on 
account of dysfunctional uterine bleeding. They also found that obesity did not appear to 
be related to menstrual blood loss. However obesity was a factor in the referral of some 
of these women for endometrial ablation as an alternative to hysterectomy for treatment 
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of excessive menstrual bleeding and consequently, the mean BMI and the mean 
menstrual blood loss was higher than normal in their study population (Deeny & Davis, 
1994). 
Nutrition also plays an important role in the development of iron deficiency. 
Consumption of iron-rich foods, supplements, and enhancers of iron absorption could all 
potentially increase iron stores in individuals with sub-optimal iron status. In a 16 week, 
randomized (stratified block) placebo-controlled trial, Heath et al. (2001) investigated the 
efficiency of a dietary regime involving increased consumption of these factors, as well 
as decreased consumption of inhibitors of iron absorption, for increasing iron stores in 7 5 
adult New Zealand women aged 18 to 40 years with iron depletion or mild iron 
deficiency as classified by the authors (serum ferritin <20 J.Lg/L, hemoglobin ~120 giL). 
Women were excluded if they were pregnant or lactating, had irregular menstruation, 
health problems or were consuming medication likely to effect iron status, or were 
vegans; and participants were asked not to take iron, vitamin C, or calcium supplements 
during the study or to donate blood. The participants were assigned to receive either 
placebo, supplement (50 mg iron/day as amino acid chelate) or a diet regime consisting of 
individual dietary counselling to increase the intake and bioavailability of dietary iron. A 
fasting, morning venipuncture blood sample was taken each month to assess iron status 
and dietary iron intake was assessed at weeks 4, 8 and 16 via a validated computer-
administered Iron Food Frequency Questionnaire. Serum ferritin increased in women 
receiving supplement (n=16) and diet (n=22) by 59% (p=O.OOl) and 26% (p=0.068) in 
comparison to the placebo group {n=l9), respectively. The authors suggest that the 
improvement achieved in response to dietary change was considerably less than that 
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achieved with supplementation due to the difficulty associated with embarking on and 
sustaining a dietary regime that primarily requires an increased consumption of the more 
easily absorbed, and nonheme absorption enhancing, heme iron from meat/fish/poultry 
(Heath, Skeaff, O'Brien, Williams, & Gibson, 2001). 
We collected data on bleeding and gynecological history, the amount of menstrual 
losses and BMI. The association of these variables with iron status was analyzed, keeping 
in mind that a complete picture of what caused low iron stores could not be made largely 
because data on dietary intake or iron absorption were not collected in the present study. 
2.3.4 Cognition and Fatigue 
An abundance of research has been produced on the affects of iron deficiency 
anemia for some time, particular in the growing infant or child, but only recently have 
groups focused on the clinical impact of iron deficiency without anemia in women o f 
reproductive age. Research on the impact of iron deficiency without anemia in this type 
of population, similar to our study cohort, has focused primarily on three intersecting 
areas: (i) cognition and memory, (ii) exercise capacity and physical performance, and (iii) 
general health and fatigue. 
(i) Cognition and memory 
Most of the work on the neurophysiological underpinnings of cognitive 
impairment associated with iron deficiency has been performed using animal models. 
However, the results of one clinical study suggested that body iron stores are relevant to 
specific neurophysiological processes supporting attention. An association between 
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ferritin concentrations and electroencephalographic (EEG) asymmetry was shown in 69 
normal male (n=17) and female (n=52) university students studying introductory 
psychology. Consistent with these EEG asymmetries, iron status was also significantly 
related to performance on two cognitive tasks {Tucker, Sandstead, Penland, Dawson, & 
Milne, 1984). 
Other studies have shown that iron deficiency can affect cognition as assessed by 
test performance. A recent blinded placebo trial of 113 women (30 iron-sufficient, 53 iron 
deficient, 30 iron-deficient anemic), showed that iron status alters cognitive functioning 
in women during reproductive years. Murray-Kolb et al. (2004) administered eight 
computerized cognitive performance tasks from the Detterman's Cognitive Abilities Test 
at baseline and again after 16 weeks of consuming iron supplements or placebo. While 
the investigators have yet to publish the study in full, in an abstract they state that women 
who started the study iron-deficient without anemia performed with significantly less 
accuracy then women who were iron sufficient. Repeated measures analysis of 
covariance (ANCOV A) also revealed an improvement in performance as well as time to 
complete attention, memory, and learning tasks in women who improved their iron status 
over time (Murray-Kolb, Whitfield, & Beard, 2004). 
A relationship between iron status, and mean performance on a measure of 
sustained attention (Bakan Vigilance Task) was also observed in 14 obese (BMI >31.5) 
dieting women. Hemoglobin (r = 0.72, p<0.01) and transferrin saturation (r = 0.86, 
p<O.Ol), for those subjects whose hemoglobin declined, were both positively correlated 
to sustained attention task performance at 15 weeks. Based on these results the authors 
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suggest that an inability to sustain attention may be an early sign of developing iron 
deficiency in obese dieting women (Kretsch, Fong, Green, & Johnson, 1998). 
The iron status of adolescents and young women also appears to impact cognitive 
performance. In a double-blind placebo trial, non-anemic (hemoglobin > 11.5 g/dL for 
African Americans, hemoglobin >12.0 g/dL for white) iron deficient (serum ferritin 
<12.0 J.Lg/L) adolescent girls also demonstrated improved verbal learning and memory 
with iron supplementation. Seventy-three girls aged 13-18 enrolled at four different high 
schools, randomized to receive either a ferrous sulphate preparation (n=37) or a placebo 
(n=36) twice daily for eight weeks, had their cognitive functioning assessed at baseline 
and eight weeks via three measures of attention and one multi-component test of verbal 
learning and memory- The Hopkins Verbal Learning Test (HVLT). Multiple regression 
analysis revealed that iron treatment had no significant effect after eight weeks on any of 
the three measures of attention. However, on the total recall score of the HVLT, iron 
supplemented girls showed a significant improvement compared to controls (p<0.02) 
with a change in serum ferritin significantly correlating with change H VLT ( r = 0 .21, 
p<0.04). The authors suggest that a ceiling effect may have limited the ability of some of 
the measures of attention to detect changes between groups (Bruner et al., 1996). Groner 
et al. (1986) also assessed the effects of oral iron therapy on psychometric test scores and 
the association between iron status and test scores using a double-blind randomized 
clinical trial. Thirty-eight inner-city pregnant females aged 14-24 were chosen as subjects 
because of their high risk for being iron deficient due to both their socioeconomic status 
and extra iron demand during pregnancy and because pregnancy required them to attend a 
health facility on a regular basis. Only subjects who were :S16 weeks gestation (i.e., not in 
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a period where the demand for iron increases greatly) and who had hematocrits > 30% 
(i.e., not severely iron-deficient) were enrolled in the study with 25 completing the study. 
The experimental group (n=16) received an iron supplement, the equivalent of 60 mg of 
elemental iron daily, along with prenatal vitamins and the control group (n=9) received 
only prenatal vitamins. While the authors do not provide an explanation for the uneven 
distribution of dropouts (1 0 from control, 3 from experimental group), they point out that 
the principle investigator was not a ware oft he uneven distribution nor did any o f the 
dropouts state that she was aware that she was taking vitamins without iron. The dropouts 
also did not change the composition of the two groups in terms of demographic, 
hematological, or psychometric variables. Hematological status (Hemoglobin, Hemocrit, 
MCV, Mean Corpuscular Hemoglobin (MCH), and ferritin) and performance on six 
psychometric tests were assessed at baseline and after one month of treatment: five 
focusing on short-term memory and attention span and one vocabulary test that was 
expected to remain relatively constant. The experimental group showed significant 
improvement on the most sensitive measure of short-term memory (Digit Symbol score, 
p<0.005) and three subtests (one subsection of Consonant Trigrams, two subsections of 
the Rey Auditory Verbal Learning Test), while the control group showed no significant 
change, as revealed by one-tailed paired t-tests. When the change between baseline and 
post-treatment scores were compared between the groups, the experimental group showed 
significant or borderline greater improvement than controls on three tests (Arithmetic 
score, p<0.02; subsection of Consonant Trigrams, p<0.05; Digit Symbol score, p<0.08). 
No correlation was found between the raw or change scores of any hematological 
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measure and any of the psychometric test scores (Groner, Holtzman, Charney, & Mellits, 
1986). 
(ii) Exercise capacity and physical performance 
Women's iron status has also been associated with exercise capacity and physical 
performance. Factors related to reduced body iron storage, but unrelated to decreased 
oxygen-transport capacity of the blood, have been suggested as a putative cause. When 
physical activity level and fat-free mass were controlled for, iron depleted (serum ferritin 
<12 J..Lg/L) non-anemic (hemoglobin> 120 giL) women (n=15) aged 19-36 were shown to 
have a significantly lower V02max than women with normal iron status (n=15), with the 
difference in V02max significantly associated with serum ferritin concentration, but not 
hemoglobin concentration (Zhu & Haas, 1997). Furthermore, iron supplementing non-
anemic, iron-deficient women improves progressive fatigue resistance during dynamic 
knee extensor exercises and endurance times during treadmill running (Brutsaert, 
Hemandez-Cordero, Rivera, Viola, Hughes, & Haas, 2003; Rowland, Deisroth, Green, & 
Kelleher, 1988). In a randomized clinical trial, 20 non-anemic (as defined by a rather lax 
cut-off of hemoglobin >110 giL) iron-deficient (serum ferritin <20 J..Lg/L) women aged 
18-45 received either iron (n=10) or placebo (n=10) and were assessed on progressive 
fatigue resistance for 6 weeks, via 2-3 second maximal voluntary static contractions 
(MVC) with dynamic knee extensions. Iron status increased significantly, the rate of 
decrease of MVC was reduced in the iron group compared to placebo (p = 0.01), and 
MVC was significantly higher after treatment at some assessment times (Brutsaert et al., 
2003). Similarly, 14 non-anemic (hemoglobin >120 giL) iron-deficient (serum ferritin 
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<20 Jlg/L) high-school adolescent runners received either iron (n=7) or placebo (n=7) for 
one month, but were assessed on treadmill endurance time. Iron status improved in 
patients taking iron, decreased in patients taking placebo, and treadmill endurance times 
improved significantly in the iron-treated runners compared with controls, with the latter 
showing a decline (Rowland et al., 1988). 
(iii) General health and fatigue 
Clinical studies of non-anemic iron deficient women have also focused on fatigue. 
Anecdotal clinical reports documenting the occurrence of symptoms of chlorosis without 
anemia (then determined via qualitatively and quantitatively normal red blood cells and 
later via hemoglobinometry) have been reported since the 19th century and the first half of 
the 20th century. Chlorosis, known as the "green sickness", was considered to be a 
common malady characterized by a hypochromic anemia that responded to iron therapy. 
It is now accepted that the basic pathogenesis was iron deficiency. It was not until the late 
1950s that a group undertook the first controlled clinical trial, comparing response to oral 
iron and a bismuth subcarbonate placebo in chronically fatigued, non-anemic women 
(Beutler, 2002; Beutler, Larsh, & G umey, 1960). In a double-blind crossover clinical 
trial, 30 otherwise healthy non-anemic (hemoglobin> 120 giL) women complaining of 
chronic fatigue (with or without symptoms such as headaches, dizziness, and 
nervousness) received iron tablets and placebo tablets each for three months with an 
inter-treatment interval of one month. An initial one month baseline observation period 
was used to exclude patients who improved spontaneously or who were non-compliant. 
Beutler et al. (1960) reported that women who showed no signs of iron on bone marrow 
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examination taken at baseline had a significantly better symptomatic response to iron 
than placebo, but the same did not occur in women in whom marrow iron was present 
(Beutler, Larsh, & Gurney, 1960). 
More recently, Verdon et al. (2003) confirmed the results of Beutler et al. (1960). 
They showed that iron supplementation may benefit women of reproductive age with 
unexplained fatigue in the absence of anemia, in whom baseline serum ferritin 
concentrations were =::50J.1g/L. They measured the level of fatigue in 144 women aged 18 
to 55 presenting with unexplained fatigue via a 10 point visual analogue scale in a double 
blind randomised placebo trial. Women were excluded if they had hemoglobin 
concentrations <117 giL, another obvious physical or psychiatric cause for fatigue, or 
chronic fatigue syndrome. One hundred thirty-six women completed the study with 71 
receiving ferrous sulphate equivalent to 80 mg/day of elemental iron daily and 65 
receiving placebo. Fifty-one percent had serum ferritin concentrations 90J.lg/L and 85% 
=::50J.1g/L. Mean age, serum ferritin concentration, hemoglobin concentration, level of 
fatigue, depression, and anxiety were similar in both groups. The level of fatigue after 
one month decreased by 29% in the group receiving oral iron, 13% in the control group 
and the difference in the decrease between both groups was significant as revealed by two 
tailed t-test (p = 0.004). A sub-group analysis also showed that women with ferritin 
concentrations <50J.1g/L improved with oral iron supplementation. A greater decrease in 
anxiety was also observed in the iron treated group ( -1.7, SD = 6) than in the placebo 
group (1.3, SD = 6) (p=0.003) (Verdon et al., 2003). 
In addition to experimental studies using an iron supplement intervention, a large 
non-experimental cross-sectional cohort study, using baseline and follow-up data from 
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the first two years of the Australian Longitudinal Study on Women's Health (ALSWH), 
found an association between self-reported iron deficiency and general health and well-
being, vitality and fatigue in Australian Women. Twenty-four percent of 14,762 young 
(18-23 years) and 31% of 14,072 middle-aged (45-50 years) women reported yes to ever 
having been told by their doctor that they had low iron. Both age-groups' mean scores for 
the vitality subscale and for the physical and mental component summary scores of the 
MOS short-form survey (SF-36) were significantly lower than the mean scores of women 
who reported never having been told by their doctor that they had low iron (p<0.0001) 
(Patterson, Brown, Powers, & Roberts, 2000). 
In follow-up to the associations observed in the ALSWH study, the effects of iron 
deficiency without anemia on general health, well-being, and tiredness was systemically 
investigated in a randomized controlled clinical trial of Australian women aged 18 years 
or older. Fifty-two iron-deficient and 24 iron-replete menstruating women matched for 
age and parity, were recruited for the study, with the former randomly allocated within 
their age and parity category to receive dietary treatment or supplements. Participants 
allocated to the supplement group were asked to take 350 mg ferrous sulphate daily for 
12 weeks and participants allocated to the diet group were asked to follow a high iron diet 
(providing approx. the recommended 2.25 mg per day intake of absorbed iron) for the 
same period. Treatment of iron deficiency (serum ferritin <15 J.Lg/L or serum ferritin 15-
20 J.Lg/L with two other hematological parameters indicative of iron deficiency) with 
either supplementation or a high iron diet resulted in improved mental health and 
decreased fatigue among menstruating women (P<O.Ol) (Patterson, Brown, & Roberts, 
2001). 
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We looked at the association of iron status with various quality of life parameters, 
as measured via the SF-36, in a population of men and women including individuals who 
are symptomatic and asymptomatic obligate carriers of the Val2016Ala allele mutation 
that underlies mild hemophilia A. 
2.4 Summary 
In Newfoundland & Labrador there are an unusually high proportion of mild 
cases of hemophilia A and although mild hemophilia has been reported in the literature 
since 1953, there is a paucity of studies with adequate power addressing bleeding in mild 
hemophiliacs. Furthermore, while the literature that has evaluated iron status in male 
hemophiliacs - with only a few of the hemophiliacs studied being of mild severity -
suggests that iron deficiency is likely not a complication of the disease, the literature on 
this topic is scarce. 
It is also not known whether female carriers of the gene that underlies mild 
hemophilia A tend to be more iron-deficient than non-carrier women. Using the PBAC to 
assess menstrual blood loss in women with bleeding disorders, menorrhagia (PBAC score 
> 100) was putatively confirmed in 57% hemophilia carriers, and in only 29% of control 
women. And using the accurate and reliable alkaline hematin method to measure 
menstrual losses, and various parameters reflecting the iron state of the body, Hallberg et 
al. showed that signs of iron deficiency are present in women who experience more than 
60 ml of blood loss and occurs in 67% of women whose menstrual exceeds 80 ml. 
Therefore, it is worth investigating whether carrier women have greater menstrual losses 
and as a result, tend to have lower iron stores. 
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In general, there is also a need to document the iron status of individuals residing 
in Newfoundland and Labrador. Studies of iron status among adult women in Canada are 
greatly lacking and are essentially non-existent for women in Newfoundland and 
Labrador. Finally, literature also suggests that iron depletion can possibly have a 
significant effect on cognition and fatigue and may more generally affect quality of life. 
Chapter 3 
Research Question 
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3.0 Research Questions 
Primary Question: 
What is the prevalence of iron depletion (female serum ferritin< 50, 40, or 20 !J.g/L; male 
<50, 40, or 30 !J.g/L) and iron deficiency (female serum ferritin< 11 !J.g/L; male< !J.g/L 
24) in a population residing in Newfoundland and Labrador, sub-grouped by gender, 
V al20 16Ala allele mutation status, and menstrual status? 
Secondary Questions: 
Does iron depletion and iron deficiency impact the quality oflife, as measured by the SF-
36 questionnaire, of a population residing in Newfoundland and Labrador? 
Is iron status associated with menstrual blood loss (PBAC score), bleeding history, Factor 
VIII level, BMI, and age in a population residing in Newfoundland and Labrador, sub-
grouped by gender, Val2016Ala allele mutation status, and menstrual status? 
What is the sensitivity and specificity ofMCV, RDW, and hemoglobin for diagnosing 
suboptimal iron status in women as defined by various serum ferritin concentrations? 
3.1 Outcome Measures 
3.1.1 Primary Measure 
• The prevalence of suboptimal iron status (iron depletion or iron deficiency) in (i) 
women vs. men, (ii) menstruating women vs. non-menstruating women, (iii) 
menstruating carrier women vs. menstruating control women, and (iv) affected 
men vs. control men. 
3.1.2 Secondary Measures 
• Median serum ferritin concentration 
• Prevalence of menorrhagia (PBAC > 1 00) 
• Mean PBAC score 
• Bleeding history 
• Age 
• BMI 
• Factor VIII level 
• Mean scores of the 8 domains and 2 summary component scores of the SF-36 
• The sensitivity and specificity ofMCV, RDW, and hemoglobin for diagnosing 
suboptimal iron status 
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Chapter4 
Materials & Methods 
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4.0 Study Design 
This is a two-year cross-sectional cohort clinical study. The study has several 
components. The first is an objective clinical description of a cohort of patients carrying 
the Factor VIII mutation. This component served to determine the b urden o f b leeding 
illness, Factor VIII replacement therapy, prevalence of inhibitor formation and potential 
blood borne pathogen associated disease in this kindred with mild Hemophilia A. 
Information from this clinical assessment was also used to seek potential environmental 
factors associated with the severity of clinical expression. Comparison of musculoskeletal 
and quality of life scores with siblings matched for age was used to further objectively 
delineate the burden of illness and potential psychological impact of carrier status in this 
population. 
In recognition of the need to document the prevalence of iron deficiency in rural 
Newfoundland and Labrador, an additional component was later created; namely, an 
objective description of iron status in a cohort of patients, including those carrying the 
Factor VIII mutation. This component is the focus of this thesis and it has served in 
documenting the prevalence of iron deficiency and iron depletion, its association with 
blood loss and other potentially influential variables, and the potential impact iron 
deficiency and/or iron depletion may have on various quality of life parameters. 
4.1 Study Population 
The study involved affected patients with mild hemophilia A, carrier females who 
have been shown by molecular analysis to have the same causative Factor VIII mutation 
(val2016ala), unaffected control males, and non-carrier control females. Due to a founder 
effect, the majority of patients belonged to one very large kindred comprising over 1900 
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individuals. Another 5 smaller families known to have this mutation were included 
although their precise ancestral connection to the larger kindred is unclear. Most of the 
participants resided in Newfoundland and many had settled in roughly the same rural area 
in the central region of the province. 
4.1.1 Inclusion Criteria 
1. All individuals :::18 years of age and meeting the requirements for the 
following cohorts were considered eligible: 
Cohort A: Affected males and homozygous females who test positive for the 
val2016ala mutation. 
Cohort B: Unaffected males who test negative for the val2016ala mutation. Normal 
male siblings of the primary patient population will be used preferentially followed 
by age and sex-matched controls from the community. 
Cohort C: Carrier females who are heterozygous for the val2016ala mutation, 
regardless of whether they are manifesting symptoms. 
Cohort D: Non-carrier females who test negative for the val2016ala mutation. 
Normal female siblings of the primary population will be used preferentially followed 
by age and sex-matched controls from the community. 
Women were also classified as menstruating or non-menstruating. Non-menstruating 
women were either post-menopausal or had a hysterectomy. 
2. Individuals must be able to give informed consent to participate. 
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4.1.2 Exclusion Criteria 
1. Individuals living out-of-province who are unable to comply with the 
assessments required of the study. 
2. Pregnant individuals 
3. lndividual(s) judged to be non-compliant by the treating physician. 
4.2 Patient Recruitment 
4.2.1 Patient Identification 
Patients eligible for the study were identified through the hemophilia program registry 
and family histories on file in the genetics department. Based upon pedigree information, 
eligible individuals were approached to participate by the genetic counsellor. Surviving 
members from the 6 known mutation positive kindreds born since 1915 were contacted 
by the genetic counsellor to discuss study participation. For patients or relatives unknown 
to either the hemophilia program or genetics, contact was only made via a known family 
contact. It was emphasized that participation was voluntary and in no way would 
interrupt the care offered through the hemophilia comprehensive care team. 
4.2.2 Patient Enrollment 
Patients already known to the hemophilia clinic or to the genetics department were 
contacted directly to discuss study participation. Patients unknown to the hemophilia 
clinic or to the genetics clinic were approached only via a known family contact. Health 
professionals in the area were asked to make families aware of the study and to provide 
contact numbers for the investigators. Community forums were also used to introduce the 
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study objectives and encourage participation. Physician or self-referral was considered 
acceptable. 
4.2.3 Sample Size 
This study was undertaken as an ad hoc component of a 2 year cross-sectional study 
aimed at defining the clinical impact of mild hemophilia A. The clinical impact of mild 
hemophilia A study attempted to recruit about 80 affected males, 100 female carriers and 
200 unaffected family controls from the Twillingate area kindred. It seemed improbable 
to recruit any more than that number due to inherent family size and availability of data 
on members of the kindred. Eighty-four carrier women, 47 affected men, and 95 adult 
controls were recruited, and studied for the purpose of this thesis, including 46 
menstruating carriers and 35 menstruating control women. Based on the results of a study 
by Kadir et al. (1999) that documented the prevalence of menorrhagia in control (29%) 
and carrier women (57%) for the gene that underlies mild hemophilia A, and given that 
iron deficiency is generally present in 67% of women whose menstrual losses exceed 80 
ml (Hallberg et al., 1966)~ it is estimated that 19% (95%CI 6-32%) of menstruating 
control females and 38% (95%CI 24-52%) of menstruating carrier females will be iron 
deficient or have serum ferritin concentrations <11 ~. 
4.3 Assessment 
4.3.1 Laboratory evaluation of iron status 
4.3.1.1 Overview 
While bone marrow biopsy is widely considered to be the gold standard for 
clinical assessment of iron status, the semi-quantitative nature of the examination and 
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other limitations has caused some debate. Some of the limitations of this method include, 
abstraction o fb one marrow is invasive, them ethods subjective nature si nee the result 
depends on the skill of the investigator, sufficient amount of available marrow stroma, 
and a meticulous staining technique. The semi-quantitative method also produces results 
that may reflect a wide range of actual available iron (Barron, Hoyer, & Tefferi, 2001; 
Ganti, Moazzam, Laraia, Tendulkar, Patti, & Mehdi, 2003). Serum ferritin is widely 
accepted to be the most useful single measure of iron status due to its accuracy in 
reflecting body stores, its early detection of iron deficiency, and its high feasibility, but it 
also has limitations. In addition to the direct measurement standard of bone marrow 
biopsy, indirect clinical methods for measuring iron status either alone or in combination, 
include, serum ferritin, complete blood count (CBC), transferrin saturation, red cell 
protoporphyrin (RCP), serum iron, and serum transferrin receptor. 
4.3.1.2 Serum Ferritin Concentration 
Serum ferritin concentration is a sensitive quantitative measure reflecting the 
amount of stored iron in the body and is the most widely used method to discriminate 
between subjects who are and are not iron deficient. Addison et al. (1972) first described 
an immunoradiometric assay for detecting ferritin in the serum and this method was used 
to report the concentration of serum ferritin in normal, iron-deficient anemic patients and 
patients with iron overload. In their study, ferritin was shown to be present in normal 
serum in concentrations between 10 and 1 00 ~giL. for the first time establishing it as a 
normal constituent of serum (Addison, Beamish, Hales, Hodgkins, Jacobs, & Llewellin, 
1972). Using the same technique, Jacobs et al. (1972) showed that ferritin is normally 
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present in the circulation in concentrations between 1 0 and 200 J.lg/L. Less than 1 0 J.lg/L 
was associated with transferrin saturations less than 16% and it was presumed that this 
reflected impaired iron delivery to the plasma pool. Therefore, a serum ferritin 
concentration of 10 J.lg/L was considered a reflection of the lower limit of storage iron 
adequate to meet the demand of erythropoiesis (Jacobs, Miller, Worwood, Beamish, & 
Wardrop, 1972). The relationship between serum ferritin concentration and the amount of 
storage iron in normal subjects was more strongly established by Walters at al. (1973). 
The authors showed a strong correlation (r = 0.83; p<O.OOl) between serum ferritin 
concentration and storage iron as measured by the accurate method of quantitative 
phlebotomy. Serial phlebotomies were performed at weekly intervals until hemoglobin 
concentration fell below 110 g/L and was maintained at this level and the transferrin 
saturation was consistently below 15% (Walters, Miller, & Worwood, 1973). 
The diagnostic performance of serum ferritin concentration as a measure of iron 
stores has been consistently validated against bone marrow examinations (Ali, Luxton, & 
Walker, 1978; Mazza, Barr, McDonald, & Valberg, 1978; Hallberg et al., 1993). Taking 
a serum ferritin concentration of~12J.1g/L as a diagnosis of iron deficiency as determined 
by no appearance of iron upon examination of bone marrow fragments, it could be 
determined from the data presented by Ali et al. (1978) that the test had a sensitivity of 
71% and a specificity of 100% for use in a mixed hospital population, with many of the 
false negative cases demonstrating the presence of hepatic, malignant, or inflammatory 
conditions. 
Serum ferritin has also been shown to be diagnostically superior to other measures 
of iron status. One hundred patients referred for bone marrow aspiration on account of 
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their condition had blood samples taken within 48 hours of aspiration so as to measure 
hemoglobin concentration, serum iron concentration, percent transferring saturation, and 
serum ferritin concentration. These indirect methods of iron status assessment were 
independently validated against bone marrow examination. Using a serum ferritin cut-off 
of< 18 J.l.g/L, a serum iron cut-off of< 65 J.l.g/dL, and a transferrin saturation of <20%, 
the tests had a sensitivity of 79%, 84%, 84% and a specificity of 96%, 43%, and 63%, 
respectively. Using any of the two tests together in combination did not improve 
diagnostic performance (Mazza et al., 1978). The iron status of 203 women, classified 
according to the presence or absence of stainable bone marrow iron, were also examined 
via a radioactive iron absorption test, serum ferritin, hemoglobin, MCH, MCV and 
transferrin saturation. The diagnostic efficiency to correctly classify subjects as iron 
replete and iron deficient was superior for serum ferritin compared to all the other tests 
examined. A serum ferritin concentration <16 J.l.g/1 resulted in a specificity of 98% and a 
sensitivity of 75%. Most of the 25% of iron deficient subjects that were falsely classified 
as iron replete had serum ferritin concentrations in the range of 16-30 J.l.g/L (Hallberg et 
al., 1993). 
The most extensive review of the diagnostic value of laboratory testing for the 
diagnosis of iron deficiency anemia was conducted by a research team from McMaster 
University. In a systematic overview of the relevant literature, Guyatt et al. (1992) 
identified 55 studies containing the results of laboratory tests and histological 
examination of bone marrow for at least 50% of an identifiable patient group. The target 
population was patients over 18 years old with low levels of hemoglobin (<130 giL for 
men, <11 0 giL for women) and a study was included if 10% or more of the patients met 
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this criteria. Studies also had to quantify MCV, transferrin saturation (TS), serum ferritin, 
RCP, RDW, or red cell ferritin (RCF) and at least test sensitivity had to be calculable 
based on bone marrow examination where at least 50% of an identifiable subgroup of 
patients were assessed with the gold standard. It was concluded that serum ferritin 
radioimmunoassay is an extremely powerful test for the diagnosis of iron-deficiency 
anemia. The areas under the Receiver Operating Characteristics (ROC) curves (y-axis 
representing sensitivity, x-axis representing !-specificity) for all the tests were calculated 
with a greater area denoting a more powerful test. Serum ferritin had a mean area under 
ROC curve of 0.95 (95% CI: 0.94-0.96; n=2579) and was significantly different from all 
other tests (p<O.OOl). The extreme likelihood ratios of the test observed at intervals of 15-
25 Jlg/L (LR=8.83; 95%CI: 7.22-10.44) and ~15 Jlg/L (LR=51.85; 95%CI: 41.53-62.27) 
also reflect the power of the test. MCV determination proved significantly more powerful 
than all the other tests (p<O.OOl) except serum ferritin, but the difference between RCP, 
TS, and MCV results all could have occurred by chance (p>0.05). Using a cut-off of< 70 
11m3, MCV had a likelihood ratio of 12.47 (95%CI: 6.13-18.81). Based on these results, 
the authors conclude that serum ferritin should be the only measure used to determine 
iron deficiency. They also suggest that the traditional cut-off values between 12 and 20 
Jlg/L use by laboratories is not optimal, since the likelihood of iron deficiency in a 
general population does not start to drop until values are higher than approximately 40 
Jlg/L (Guyatt et al., 1992). 
A wide range of cut-off values for serum ferritin have been set via comparing the 
diagnostic performance of serum ferritin measures with bone marrow examinations. 
Hallberg et al. (1993) summarize cut-off values used by various researchers, illustrating 
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the wide range (15-27 J.lg/L) of cut-offs used and point out that these values were 
determined without using the international standard proposed in 1985 (ICSH, 1985) In 
their study they showed that iron deficiency could be defined by serum ferritin < 16 J.lg/L, 
as signs of iron deficient erythropoiesis were already present at this level. To determine 
when the first signs of iron deficient erythropoiesis can be observed, a regression analysis 
was performed on serum ferritin and on all of the hematological parameters included in 
the study. As serum ferritin levels decreased, a significant reduction occurred in all of the 
hematological parameters studied (Hb: r=0.86, p<0.01; MCH: r=0.93, p<O.Ol; MCV: 
r=0.92, p=0.04; and TS: r=0.84, p<0.05). Iron deficient erythropoiesis was already 
present at serum ferritin <16 J.lg/L. A graphical least squares analysis describing the 
relationship between serum ferritin and the hematological data in all subjects, suggested 
that the decrease in hematological measurements starts very early during the development 
of iron deficiency (serum ferritin= 25-40 J.lg/L) and hemoglobin concentrations decrease 
as soon as iron stores are empty (Hallberg et al., 1993). 
Physiological variables such as inflammation of chronic disease, liver disease, and 
malignancy must be controlled for when measuring serum ferritin c oncentration, A n 
approximate three-fold rise in serum ferritin, independent of iron stores is seen in patients 
with infection or inflammation, and nearly five-fold in patients with liver disease (Cook 
et al., 1990). Serum ferritin may be elevated as a part of an acute phase reaction. The 
measure is not reliable for ruling out iron deficiency in women of reproductive age for 
more than a month after febrile illness (Eskeland, Baerheim, Ulvik, & Hunskaav, 2002). 
In a study of 252 hospitalized subjects with anemia or disorders in iron metabolism, 
Lipschitz et al. (1974) showed that inflammation, liver disease and increased red-cell 
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turnover elevated the serum ferritin concentration independent of iron stores. When 
patients with inflammation and liver disease were compared with a control group with a 
variety of disorders exclusive of the former, serum ferritin values progressively increased 
in the groups with greater amounts of marrow hemosiderin, but at each grade of marrow, 
iron values in patients with inflammation and liver disease were much higher (p<O.OS) 
(Lipschitz, Cook, & Finch, 1974). 
In the present study serum ferritin concentration was measured using the Access 
analyzer. The lower limit of the normal physiological serum ferritin range (observed 
central 95% interval of serum ferritin), established from reference values taken from the 
"normal" population was 11 J.lg/L for women and 24 J.lg/L for men. Values below these 
levels defined iron deficiency. Mild iron deficiency is not well defined. Cut-off values of 
20, 40, and 50 J.lg/L and cut-off values of 30, 40, and 50 J.lg/L were used to measure the 
frequency of mild iron deficiency in women and men, respectively. 
4.3.1.3 Complete Blood Count: Mean Cell Volume, Red Cell Distribution Width, & 
Hemoglobin 
The primary role of a complete blood count (CBC) with respect to iron status is to 
rule out the hematological effects of low iron status, rather than iron deficiency per se. 
Measures included in a CBC that are parameters of iron status include hemoglobin 
concentration and red blood cell indices; namely, MCV and red blood cell distribution 
widthRDW. 
Hemoglobin has been used longer than any other measure for iron status. 
Hemoglobin concentration only provides a quantitative measure of the severity of iron 
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deficiency upon the development of anemia; that is, a normal blood film does not rule out 
low iron status, only its hematological effects. Hemoglobin is a relatively insensitive 
index of iron deficiency, falling only in the later stages. The measure lacks sensitivity; 
that is, there is an overlap between values of normal and iron deficient populations 
(Garby, Irnell, & Werner, 1969), and has a low specificity, since other nutritional 
deficiencies, genetic disorders, and chronic infections can limit erythropoiesis. 
Red cell indices are the basis for classifying anemias and in various combinations 
are used to gauge the severity of iron deficiency. MCV is derived from other direct CBC 
measures; that is, it is calculated be dividing the hematocrit by the red blood cell count. 
MCV is reduced when iron deficiency becomes severe or at the same time when anemia 
starts to develop. S light microcytosis ( 70-80 fl) often occurs in the anemia of chronic 
disease, but more pronounced microcytosis greatly increases the specificity once 
thalassemia has been excluded (Cook & Skikne, 1989). RDW is a quantitative 
measurement of the variation in red blood cell volume and is equivalent to the 
microscopic assessment of the degree of anisocytosis. It is expressed as either the 
standard deviation (SD) or as the coefficient of variation (ratio of SD and MCV) of the 
red cell volume distribution. 
In the present study, CBC was analyzed using a Coulter STKS. The MCV lower 
limit for both women and men was set at 80 fL and the RDW upper limit was set at 14.5 
units. The hemoglobin concentration lower limit was 120 giL for women and 140 giL for 
men. 
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4.3.2 Factor VIII Level 
Chromogenic (COAMATIC) Factor VIII coagulant (FVIII:C) assays were 
performed on all study participants using a Futura Beckman Coulter. According to the 
International Society on Thrombosis and Haemostasis (ISTH) standards, mild hemophilia 
was defined by factor levels between 5 and 40% (0.05 to 0.40 U/mL) (White et al., 2001). 
4.3.3 Questionnaires 
4.3.3.1 MOS short-form survey (SF-36) 
The SF-36 was constructed to represent two major dimensions of health -
physical and mental - and is composed of 36 items which are scored as eight multi-item 
scales, a health transition scale, and two overall summary scores: the physical component 
summary score (PCS) and the mental component summary score (MCS). The eight scales 
are scored from 0 to 100, with a higher score denoting a better health state. The summary 
scores are compared with norms from a reference population, such that the population 
average is set at 50. Thus, a PCS or MCS score below 50 indicates worse physical or 
mental health, while a score above 50 indicates better health than the reference 
population (Ware, Kosinski, & Gandek, 2000; Ware, Kosinski, & Dewey, 2000). 
Reported estimates of score reliability for the SF-36 scales in females exceeded accepted 
standards for measures used in group comparisons; for each scale, the median of the 
reliability coefficients across studies equals or exceeds .80, with the exception of the 
General Health scale (the median for this scale is .79). Validation of the SF-36 via 
content, construct, or criterion validation has shown that the scales generally measure 
their intended health concept and do not measure other concepts. Data on all eight scales, 
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the health transition scale and the two summary scores were collected using the self-
reported SF-36 (4-week recall) questionnaire (see Appendix A). 
4.3.3.2 Assessing Menstrual Blood Loss: the Pictorial Blood Loss Assessment Chart 
The Pictorial Blood Loss Assessment Chart (PBAC) has been increasingly used as 
a method for measuring menstrual blood loss in clinical studies (Crosignani, Vercellini, 
Mosconi, Oldani, Cortesti, & Georgi, 1997; Kittleson & Istre, 1998, Kadir et al., 1999), 
however a number of other methods have been described in the literature. Recognizing 
the need to optimally quantify and document the prevalence of abnormal blood loss, a 
literature review was conducted to determine how valid, reliable, applicable, and feasible 
existing measurement methods are likely to be in assessing menstrual blood loss in 
women with hereditary bleeding disorders. Methods for measuring menstrual blood loss, 
as described in the literature, include (i) the Alkaline Hematin method (AHM), (ii) the 
PBAC, (iii) a Menstrual Pictogram, (iv) Gynaeseal, (v) a Weighed Menstrual Loss 
method (WML), (vi) a Menstrual Recall questionnaire and a Menstrual Record 
questionnaire, and (vii) menstrual I gynaecological history (Kawaja, Scully, Barrett, & 
Walsh, 2003). 
(i) The Alkaline Hematin Method 
The most widely used objective laboratory method is the alkaline hematin 
method, although radioisotope measurement of Fe-59 labelled hemoglobin or Cr-51 
labelled red cells has also been devised (Shaw, 1977). The alkaline hematin method was 
first described by Hallberg and Nilsson in 1964, but has since undergone modification 
(Newton, Barnard, & Collins, 1977; Eijerkeren et al., 1986). Five percent sodium 
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hydroxide is used to extract hemoglobin from collected sanitary wear and towels, and to 
covert it to hematin. Originally, towels and tampons were squeezed and rubbed until all 
coloured spots had disappeared. The optical density of hematin was then measured with a 
spectrophotometer and compared to that of venous blood to determine the volume of 
menstrual blood loss (Hallberg et al., 1964). 
The method was improved by reducing the extraction time through the use of a 
Stomacher Lab Blender for homogenization of the sanitary pads (Newton et al., 1977) 
and later modified by recognizing important changes that would improve its accuracy 
(Eijkeren et al., 1986); that is, blank absorption values of tampons and towels were 
subtracted from that of menstrual blood and the volume of added blood was factored into 
the determination of menstrual blood loss if towels and tampons were not allowed to dry. 
As part of a combined laboratory and diary method for objective assessment of menstrual 
blood loss, Hurskainen et al. attempted to further simplify the method by correlating 
hemoglobin values with the absorption of venous blood, in order to validate the 
replacement of the latter procedure. The diary was used to estimate the amount of blood 
loss during collection (extraneous blood loss) (Hurskainen et al., 1998). A 
spectrophotometric alternative to the alkaline hematin method involving separate 
extraction of blood, using a detergent solution and color development with sodium 
carbonate, has also been developed (Vasilenko et al., 1988). Gannon et al. later used this 
two-stage laboratory technique, but used a Smallboy benchtop washer, instead of 500-ml 
plastic jars, to permit rapid extraction of a more complete collection of sanitary material 
(Gannon, Day, Hammadich, & Johnson, 1996). 
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Due to its extremely high validity and reliability, the alkaline hematin method is 
presently considered to be the gold standard for measuring menstrual blood loss. 
However, due to the specialized nature of the test and the time required to perform it, it is 
not available for routine clinical use (Higham, O'Brien, & Shaw, 1990). The optical 
density of hematin extracted from sanitary wear, when compared to that of a known 
volume of venous blood, has been consistently shown to be an accurate means of 
determining the volume of menstrual blood 1 oss (Hallberg eta 1., 1 962; Newton e t a 1., 
1977; Eijkeren et al., 1986; Hurskainen et al., 1998), although as mentioned, slight 
modifications have improved its accuracy. The mean recovery of blood from experiments 
that tested known amounts of blood (10 ml) added to sanitary protection, and 
subsequently converted into a stable elute, was 96.3% (SE = 0.5, n = 1 0) (Hallberg et al., 
1962) and 98% (range 91-106) (Eijkeren et al., 1986). Equal and greater volumes of 
added blood have similarly yielded highly accurate results (Newton et al., 1977; Eijkeren 
et al., 1986; Hurskainen et al., 1998). However, the most significant variable contributing 
to the loss of accuracy when using the Alkaline hematin method is from extraneous blood 
loss. For this reason, Hurskainen et al. applied the standard method in combination with 
a diary method to assess menstrual blood loss in 156 patients, enrolled in a randomized 
trial for menorrhagia, from the gynecology departments of 5 Finland universities. A clot 
and a spot the size of a 27 mm diameter Finish coin was estimated as 2 ml and 0.5 ml of 
blood, respectively. The amount of blood per one uncollected pad or tampon reported was 
determined from the average amount of blood collected per pad or tampon. 12% (range 
0-57%) of menstrual blood loss was lost during collection. 
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As illustrated via reported statistics that reflect variation, the alkaline hematin 
method is precise. Potential measurement errors contributing to random error include: 
errors resulting from hematin extraction, spectrophotometric analysis, and patients' 
collection of sanitary material. 
The alkaline hematin method would be expected to have the same accuracy 
among members of a pedigree, who are currently menstruating, but not for those patients 
who no longer menstruate. That is, menstrual blood loss of patients who no longer 
menstruate cannot be retrospectively assessed with this method. The gold standard is 
therefore only highly applicable for menstruating women. 
Although the method is highly applicable for menstruating women, it is not a 
feasible method for routine clinical use. The method requires trained laboratory 
technicians, equipment, significant time, and subjects who are motivated enough to 
collect a complete collection of soiled sanitary wear. The method also generates large 
volumes of caustic solutions and an unpleasant odour. Attempts that have been made to 
increase its feasibility include: the introduction of the Stomacher Lab-Blender which 
reduced the extraction time to a few minutes (Newton et al., 1977); the replacement of 
venous hematin absorbance with venous hemoglobin concentration (Hurskainen et al., 
1998) which made the procedure somewhat easier and cheaper; and a modification of the 
procedure involving the separate extraction of blood using a detergent solution and color 
development of smaller aliquot samples (Vasilenko et al., 1988). Since the latter 
modification requires extra equipment (washer) and the safe disposal of the washing 
liquid, it is not a feasible alternative. Despite these attempts, the alkaline hematin 
method's feasibility for use in a cross-sectional study remains extremely low. 
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(ii) Pictorial Blood Loss Assessment Chart 
The most widely used non-laboratory method is the pictorial blood loss 
assessment chart (PBAC). The pictorial method has been shown to be superior to other 
subjective methods that use weighing techniques or visual analogue scores. Devised by 
Higham et al. (1990), the PBAC takes into account the degree to which each item of 
sanitary protection was soiled with blood as well as the total number of pads or tampons 
used (Higham et al., 1990), it does not, however, pictorially account for extraneous blood 
loss (Wyatt, Dimmock, Walker, & O'Brien, 2001). The chart consists of a series of 
diagrams representing light, moderately and heavily soiled tampons or pads. A mark is 
made in the appropriate box at the time of soiling of each sanitary item and, if a sufficient 
number were used, counted in groups of five. In the initial study by Higham et al., clots 
of a diameter equal to or less than 1 em, diameter greater than 1 em, and episodes of 
flooding were similarly recorded. Patients were required to complete the chart after 
being given an explanation of how it was to be used and an instruction leaflet. 
Proportional scores are assigned for each degree of soiling (1, 5, and 10 for tampons; and 
1, 5,and 20 for pads) and the passage of clots (1 for small clots and 5 for large clots) 
{Higham et al., 1990). 
Higham et al. devised the PBAC in an attempt to create a more accurate non-
laboratory method of menstrual blood loss assessment. In their study, 30 patients were 
provided with specific sanitary protection (Tampax and Kotex Ferns super plus tampons 
and Kortex Simplicity size 2 towels), which were to be collected in plastic bags after their 
use. Twenty-eight patients submitted the chart that monitored between one and three 
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cycles each; resulting in a total of 55 assessed menstrual cycles. Following the patients' 
submission of their PBAC charts, a similar assessment, based on the collected sanitary 
wear, was made by a gynecologist. The gynecologist was blinded from the patients' 
assessments. Subsequently, independent of the PBAC results, the blood content of all 
collected sanitary material was quantified using the alkaline hematin method. In 
addition, 67 menstrual collections were assessed solely by the gynecologist using the 
PBAC and the alkaline hematin method (122 cycles in total), so as to strengthen the 
comparison ofthe PBAC with the gold standard (Higham et al., 1990). 
Taking a PBAC of > 100 as diagnosis of menorrhagia (blood loss > 80 ml as 
determined by the alkaline hematin method), Higham et al. reported that the method had 
a sensitivity of 86% and a specificity of 89% when used by patients, and a sensitivity of 
86% and a specificity of 81% when used by the gynecologist. The corresponding 
likelihood ratios (positive test) are 7.8 and 4.5, respectively. There was also a strong 
correlation between both the patient's (r=0.847) and the gynecologist's (r=0.872) 
assessment of blood loss and that of the alkaline hematin method. Reasonable agreement 
was shown between the patients' and the gynecologist's scores when scores were l ess 
than 150 (Higham et al., 1990). 
Fifty-three patients referred for endometrial ablation on account of dysfunctional 
uterine bleeding were also assessed with the PBAC (Deeny & Davis, 1994). Specific 
brands of tampons and pads were not supplied to the patients; that is, women used their 
customary sanitary material. In addition, visual analogue scores were also used to 
subjectively assess blood loss. Each patient was asked to score a 10-cm line to 
demonstrate how much trouble her periods caused her. The subjective methods were 
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independently validated against the alkaline hematin method (Deeny & Davis, 1994). 
Deeny et al., used the same PBAC cut-off score > 100 as set by Higham et al. to predict 
menstrual blood loss in excess of 80 ml (menorrhagia). The PBAC had a sensitivity of 
88%, a specificity of 52%, and a corresponding likelihood ratio of 1.8. Multiple 
regression showed that menstrual blood loss, as determined via the gold standard, was 
closely related to the PBAC (p = 0.001), but not to the visual analogue score (p = 0.724) 
(Deeny & Davis, 1994). 
Janssen et al. analyzed 489 bleeding episodes from 288 women complaining of 
heavy menstrual blood loss or suffering from an unexplained anemia. To obtain a well-
balanced distribution of menstrual blood loss, women requesting contraceptives and 
healthy volunteers were also asked to participate. Again, menstrual blood loss was 
assessed with the PBAC method and compared to the gold standard. Subjects collected 
their sanitary wear during one (n=87) or two (n=201) consecutive bleeding episodes. Like 
the Higham et al. study, sanitary wear was provided (Kortex Maxi Long pads and 
Tampax Super tampons). Only the first 57 women enrolled also assessed the size of 
blood clots, in comparison to Dutch coins. The former subgroup's collection of sanitary 
wear was also independently assessed by two investigators (Janssen, Scholten, & Heintz, 
1995). The authors calculated the sensitivity, specificity, positive predictive value, and 
negative predictive value for several PBAC cut-off scores for patients' first menstrual 
cycles. The ideal cut-off point (that with the highest sensitivity and specificity) was 
determined to be 130 (sensitivity 91%, specificity 81.9%) with a corresponding 
likelihood ratio of 5.0. However, the cut-off point at which the predictive values (PV) 
were maximized was 185 (Positive PV 85.9%, Negative PV 84.8%). The correlation 
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between the patients' subjective assessment of their first menstrual cycle and the alkaline 
hematin method was moderate (r = 0.56). The mean difference between the investigator 
scores and the patients' scores was +29.0 (SD= 103.2, SE=13.8, 95%CI=l.2-56.7) in 
favour of the subjects. Calculation of the agreement of scores under 150 yielded a mean 
difference +10.7 (SD=31.0, SE=6.1, 95%CI=-1.9-23.3) in favour ofthe subjects (Janssen 
et al., 1995). 
In an attempt to assess the accuracy of a PBAC as a method for estimating 
menstrual blood loss in women complaining of heavy periods, Reid et al. prospectively 
analyzed one menstrual cycle of 103 women complaining of excessive menstrual blood 
loss. Women were given the same tampons and sanitary towels as in the original study 
by Higham et al. As in the former studies, the PBAC was validated against the alkaline 
hematin method and an investigator objectively assessed women's menstrual blood loss 
independently. The correlation between the patients' subjective assessment of their 
menstrual blood loss and that determined by the alkaline hematin method was 0.46 
(95%CI=0.3-0.6). As a diagnostic test for menorrhagia, using a cut-off score of> 100 as 
being positive, the sensitivity was 97% (95% CI=93-100), the specificity was 7.5% (95% 
CI = 0-15.5), and the corresponding likelihood ratio 1.0. The Positive Predictive Value 
(PPV) was 62% (95% CI = 54-74) and the Negative Predictive Value (NPV) was 60% 
(95% CI = 52-72) (Reid, Coker, & Coltart, 2000). 
Since the PBAC method relies on both discrete (number of pads and tampons) and 
ordinal (degree of soiling) variables, it is more apt to require human judgement and to be 
susceptible to bias than the standard alkaline hematin method. The patient's accurate 
assessment of the degree of soiling of sanitary wear could potentially be affected by 
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subject bias. In all the studies mentioned, blood loss assessment by patients using the 
PBAC, investigators using the PBAC and investigators using the standard method, were 
done independently, thereby potentially eliminating any observer bias. 
Although a score of 100, as initially reported by Higham et al., has not been 
consistently determined to be the optimal cut-off point for diagnosing menorrhagia and 
the correlation between patient PBAC scores and those of the alkaline hematin method 
vary (r = 0.466, n = 103 (Reid et al., 2000); r = 0.84 7, n = 55 (Higham et al., 1990) ), the 
method demonstrates moderate validity. Two studies made an attempt to make 
comparisons among repeated PBAC measures and to analyze the results. Independent 
scores of the patients and the investigators showed reasonable agreement, particularly 
under scores of 150 (Higham et al, 1990; Janssen et al., 1995) and demonstrated low 
inter-observer variation. The reliability of the measurement method is moderate. 
As with the alkaline hematin method, the PBAC method is highly applicable for 
menstruating women, but is not applicable for women who no longer menstruate. The 
most significant advantage of using the PBAC method for assessing menstrual blood loss 
is that it is highly feasible for clinical use. The method does not require the collection of 
soiled sanitary wear, but rather only the simple completion of the chart by the subjects. 
Only two women out of all the subjects who participated in the studies discussed found 
the chart too difficult to fill in. The providing of pads and tampons may also be required 
to control for the varying absorption capacity of the wide variety of available sanitary 
protection (Higham et al., 1990; Deeny et al., 1994). 
(iii) Menstrual Pictogram 
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The Menstrual Pictogram has been developed as an accurate alternative to the 
PBAC and was validated against the alkaline hematin method (Wyatt et al., 2001). The 
method has an increased range of diagrams from slight to severely stained sanitary pads 
and tampons and makes the distinction between the differing levels of absorbency of 
blood into different pads (daytime or nighttime) and tampons (regular, super, or super 
plus). In addition, extraneous blood loss is estimated using three pictogram 
representations when changing feminine hygiene products. Patients are instructed to mark 
down the loss each time they changed their pad or tampon. A scoring system for the 
feminine hygiene products was devised such that each grade of staining of each brand 
was given a score in ml, although it is not clear from the methods section what was the 
rational for each particular score assignment (Wyatt et al., 2001). Similarly, 
conservative scores of 1, 3, and 5 ml were devised for each clot size. 
The study by Wyatt et al., (2001) was the only study found in the literature that 
validated the method, although it was later incorporated into a computer-aided method 
used to quantify menstrual cycle disorders (Wyatt, Dimmock, Hayes-Gill, Crowe, & 
O'Brien, 2002). Sixty-two women complaining of menorrhagia and 59 women who 
considered their blood loss to be normal were recruited for the study (Wyatt et al., 2001). 
Patients were provided with different types ofKotex Maxi napkins, Tampax tampons and 
airtight containers for their collection. Sixteen of the women did not complete the study 
because they either used other brands of sanitary wear than those provided (n =1) or they 
failed to collect all of the soiled products (n =12). Although comparisons were made 
against the standard method, it is not clear whether blood loss assessment using the 
standard method was assessed independently of menstrual pictogram scores. The 
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menstrual pictogram (excluding the scores for extraneous blood loss) had a sensitivity of 
86%, a specificity of 88% and a corresponding likelihood ratio of 7.2, in diagnosing 
menorrhagia. In addition, very good agreement between the menstrual pictogram method 
and the a lkaline hematin m ethod w as demonstrated u sing the t echnique o f m easure o f 
agreement described by Bland and Altman (k = 0.8). There was no correlation between 
the amount of blood collected on the sanitary products (as assessed by either method) and 
extraneous blood loss (r = 0.58). 
Although the menstrual pictogram method appears to be more accurate than the 
original PBAC, more studies are required to verify its validity. As mentioned, the 
rationale for the score assignments, and more generally, a verification of independent 
assessment is required to rule out potential observer bias. The authors suggested that the 
increased range of icons as well as making the distinction between the different levels of 
absorption between pads and tampons, may have explained the increased accuracy. 
The reliability of the method appears comparable to the PBAC, as demonstrated 
via a plot of the difference between menstrual pictogram and alkaline hematin blood loss 
measurement against their mean score, although inter-observer or intra-observer variation 
was not directly assessed in the study. The methods reliability is moderate. 
As with the PBAC, the menstrual pictogram method is highly applicable for 
menstruating women, but is not applicable for women who no longer menstruate. The 
method is also highly feasible for clinical use. The method does not require the collection 
of soiled sanitary wear, but rather only the simple completion of the chart by subjects. 
The provision of the specific pads and tampons scored in the study would also be 
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required to control for the varying absorption capacity of the wide variety of available 
sanitary protection (Wyatt et al., 2001). 
(iv) Gynaeseal 
Gleeson et al. investigated the use of a vaginally placed latex menstrual seal with 
regard to its suitability for the measurement of menstrual blood loss and efficacy as 
alternative sanitary protection. The Gynaeseal collection device consists of an inner cup 
and an outer collection pouch. Menstrual loss of two cycles was measured with the gold 
standard, prior to the use of Gynaeseal. Twelve women with menorrhagia and 10 with 
normal blood loss used Gynaeseal during 1 menstrual cycle. Of the 12 menorrhagia 
women asked to measure their losses at home by aspirating the fluid from the collection 
chamber, only five patients submitted a record of menstrual volume. Only 16-47% of the 
losses measured by the alkaline hematin method were collected. All of the women who 
attempted to record the blood volume reported spillage (Gleeson, Devitt, Buggy, & 
Bonnar, 1993). 
The method clearly has extremely low validity and reliability. Although the 
method is potentially applicable for menstruating women, it seems that only sufficiently 
motivated patients would be willing to use the cup. Gynaeseal also has an extremely low 
feasibility. Due to the unpleasant spillage, all the women with menorrhagia said they 
would prefer the standard method of menstrual blood collection. The cup was also messy 
to remove and the odour of the latex was offensive (Gleeson et al., 1993). 
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(v) Weighed Menstrual Loss 
The weighing of collected sanitary wear has been reported under the assumption 
that the entire menstrual loss could be accounted for by whole blood (Pendergrass, Scott, 
& Ream, 1984). Fraser et al. weighed the collected sanitary wear of 53 women (14 
currently complaining of menorrhagia, 34 without complaint of menorrhagia, and five 
who formally complained of menorrhagia) and compared the fluid volume to the blood 
volume determined by the alkaline hematin method. It was confirmed that a high 
proportion of fluid in menstrual discharge cannot be accounted for by blood content. 
Patients were supplied with "regular" or "super" sanitary pads (without "wings"), 
tampons, and labelled self-sealing polythene bags. After weighing the collected sanitary 
wear (soiled weight - original weight) hemoglobin content of each sanitary item was 
measured and the blood volume determined. For the whole study group, there was a 
strong linear correlation between total fluid volume and blood loss (r = 0.93; df= 104; p 
< .001). For using total fluid volume to diagnose menorrhagia, the sensitivity was 89%, 
the specificity 98%, and the corresponding likelihood ratio was 44.5 (Fraser, Warner, & 
Marantos, 2001). 
The authors contend that the simple method of estimation using weighed total 
fluid volume appears to be more accurate than the PBAC. They suggest the superiority is 
evident in the estimate it provides of actual blood loss and also in its diagnostic value. 
The present estimator, like the alkaline hematin method, is not subject to perception bias. 
The proposed weighing technique has a high validity and reliability. 
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The weighing technique is applicable for members of a pedigree who are 
menstruating. Total fluid volume is easier to calculate than blood loss, since it only 
requires weighing sanitary products prior to, and following, their use (Fraser et al., 2001). 
The method also has an advantage in that a variety of sanitary products could be used 
since the subject's perception of the degree of soiling is not required. The method may 
therefore be potentially much cheaper. However, women must still be able to completely 
collect their menstrual flow. Therefore, the method is more feasible than the gold 
standard, but not more feasible than the PBAC or the menstrual pictogram. 
(vi) Menstrual Record and Menstrual Recall Questionnaires 
Heath et al. attempted to validate two indirect methods (a menstrual recall and a 
menstrual record questionnaire) for e stimating the extent o f menstrual blood 1 oss. The 
methods were not validated against the alkaline hematin method, but against weighed 
menstrual loss. Young adult women (18-30 years old) were recruited by poster to take 
part in a study designed to find out about women's iron losses (Heath, Skeaff, & Gibson, 
1999). Subjects were given the Menstrual Recall questionnaire and then subsequently 
required to attend an interview where they were given instructions on how to complete 
the Menstrual Record questionnaire and how to collect their sanitary wear. The Menstrual 
Recall questionnaire required subjects to state how many "heavy" and "light" days they 
usually have during a period, how many pads and/or tampons they usually used on each 
type of day, the usual brand they used, and what was the absorbency stated on the 
product's packet (i.e. "super", regular", etc.). Largely according to manufacturers 
reported absorbency levels (g of fluid per product), products were assigned a relative 
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absorbency score ( 1, 2 , or 3 ). T he former variables, factor into the calculation o f the 
Menstrual Recall score (g) (Heath et al., 1999). Like the PBAC and the Menstrual 
Pictogram, the Menstrual Record requires each woman to record the proportion of which 
each sanitary item is soiled (in eighths for tampons and in ninths for pads). The estimated 
blood 1 oss (g) was calculated by multiplying the reported proportion o f soiling by the 
absorbency of the product (Heath et al., 1999). 
Spearman rank correlation coefficients between blood loss assessed by weighed 
menstrual blood loss and Menstrual Record and between Weighed Menstrual Loss and 
Menstrual Recall were r = 0.47 (p = 0.012) and r = 0.61 (p = 0.001), respectively. 
Individual subject results were classified into tertiles for each of the three measurement 
methods. The Record method correctly classified 66% of participants into the same 
tertile, grossly (by two tertiles) misclassified 14%, and the Recall method correctly 
classified 59% of participants into the same tertile, grossly misclassified 7% (Heath et al., 
1999). 
The Validity of both the Menstrual Recall and the Menstrual Record 
questionnaires are compromised by the fact that they were not compared against the 
standard alkaline hematin method. Both questionnaires discriminated between 1 ow and 
high levels of menstrual blood loss fairly well. Although the latter questionnaire is 
seemingly slightly more accurate and reliable than the former, both generally have a low 
validity and reliability. While the Menstrual Record questionnaire is only applicable for 
women who can menstruate, the Menstrual Recall questionnaire may be potentially used 
for assessing women who no longer menstruate. A more remote recall of menstruating 
will likely reduce its accuracy and precision, but a modification of the method may be 
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useful. The Menstrual Recall questionnaire has therefore an extremely high applicability, 
while the Menstrual Records applicability is high. 
The Record questionnaire, like the pictorial methods, is highly feasible, since it 
requires approximately the same level of participation on the subject's, and level of 
analysis on the investigator's behalf. The Recall questionnaire is quick to complete and 
analyze, and has a lower participation burden (Health et al., 1999). Each questionnaire 
has a high and extremely high feasibility, respectively. 
(vii) Summary 
Of all the methods discussed, the pictorial methods appeared to be the o ptimal 
measurement method for use in a pedigree. All the measurement methods are 
approximately equally applicable for menstruating women. The Menstrual Recall 
questionnaire was rated slightly higher because it has potential for use in assessing a 
more remote recall of losses; that is, it may also be applied to women who no longer 
menstruate. It is more likely, however, that for a more remote recall of losses, subjective 
methods such as menstrual/gynecological histories will be appropriate. There is no 
standard method for assessing menstrual blood loss in women in a clinical setting and all 
available tools have certain limitations. Comparing the alkaline hematin method and 
several diagnostic tests in a single study of individuals, more similar to the patients 
enrolled in our study, would more clearly determine which questionnaire is optimal. For 
example, many of the studies described evaluated the assessment tools in patients referred 
for menorrhagia or with known anemia, making the results less applicable to the group of 
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patients in this study. However, based on the available literature, the PBAC was used to 
assess menstrual blood loss in menstruating women. 
Pre-menopausal women enrolled in the study who were menstruating were given 
a PBAC and were asked to document their menstrual flow and return the questionnaire 
(see Appendix B). In the absence of a consistent PBAC cut-off for defining menorrhagia, 
a PBAC score :=: 100 was used. This cut-off was used by Kadir et al. (1999) in their 
assessment of menstrual blood loss and gynecological problems in patients with inherited 
bleeding disorders and was the cut-off originally suggested by Higham et al. (1990). 
4.3.3.3 Bleeding History 
Bleeding histories for both women and men were also taken as part of the 
Personal Interview Questionnaire. If participants answered "yes", "a lot", or "very much" 
to three of the first five questions under the Bleeding History section of the Personal 
Interview Questionnaire, they were considered to have a history of severe bleeding. This 
questionnaire was not pre-tested or validated (see Appendix C). 
4.3.3.4 Body Mass Index 
BMI was measured as part of the Health Status section of the self-administered 
Health Assessment Questionnaire. Participants were asked to record their height and 
weight. 
4.4 Statistical Analysis 
SPSS for Windows Version 11.0 was used to carry out all statistical analyses. 
Evidence for a difference between select groups was tested using independent Student t-
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tests for continuous variables that were normally distributed, the Mann-Whitney U test 
for those that were not normally distributed. These variables were: serum ferritin 
concentrations, hemoglobin concentration, PBAC scores, Factor VIII levels, and domain 
and component summary scores of the SF-36. Chi-square tests were used for categorical 
variables. These variables were: the prevalence of sub-optimal iron status and the 
prevalence of menorrhagia (PBAC> 1 00). Regression analysis was used to examine the 
relationship between PBAC scores, factor VIII level, age, BMI, and serum ferritin 
concentration. Lastly, the sensitivity and specificity ofMCV, RDW, and hemoglobin for 
diagnosing suboptimal iron status as defined by various serum ferritin cut-offs was 
determined. 
4.5 Data Management 
A Microsoft Access database was used for entering the data and checked for 
accuracy. When all the data was entered and reviewed, it was stored under lock and key. 
4.6 Ethical Considerations 
The study design and implementation met all the guidelines of the Tri-Council's 
policy statement and was approved by the Human Investigations Committee of Memorial 
University of Newfoundland. Participant data were stored in a separate computer 
database from individual identifiers and were linked only by patient identification 
numbers. All participants gave informed consent and were free to discontinue 
participation in the study at any time. 
Chapter 5 
Results 
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5.0 Characteristics of Women and Men 
The prevalence of co-morbid disease, iron status, and SF-36 quality of life scores 
for females and males are shown in Table 5.0. Women in general self-reported a 
clinically, lower mean (95% Confidence Interval) General Health Scale score (63.9, 59.9-
67.9 vs. 70.6, 69.5-71.7) and a higher mean Role Emotional Scale score (89.3, 85.8-92.8 
vs. 79.5, 77.7-81.3) than norms for the general U.S. female population. 
5.1 Prevalence of Iron Deficiency 
Iron deficiency was prevalent m women residing in rural Newfoundland, 
particularly in menstruating women. The prevalence of iron depletion for women and 
men as defined by serum ferritin concentrations of less than 50, 40, and 20 J.lg/L and the 
prevalence of iron deficiency as defined by serum ferritin concentrations less than 11 J.lg/L 
are shown in Table 5.1. Women are sub-grouped by mutation status and menstrual status 
and men are just sub-grouped by mutation status. The prevalence of both iron depletion 
and iron deficiency is significantly higher in women than in men and the prevalence of 
mild iron deficiency is significantly higher in menstruating women than in non-
menstruating (post-menopausal or who had undergone hysterectomy) women. Mutation 
status did not influence iron status in either women or men (Table 5.1). Six women had 
hemoglobin concentrations less than 120 giL and 11 men had concentrations less than 
140 giL, with anemia comparably observed in patients with or without the mutation (data 
not shown). 
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5.2 Serum Ferritin Concentration and Associations 
As expected, serum ferritin concentrations for females were significantly lower 
than males. Men with a history of severe bleeding had significantly lower ferritin levels 
than men without a history of severe bleeding (123.4 ~giL. 63.6-186.3 vs. 189.8 ~g/L, 
105.9-301.5; p <0.05). The serum ferritin concentrations of affected males and control 
males were not significantly different (Table 5.2). 
Women's age appeared to be associated with ferritin (r = 0.325, p <0.0001) and 
the median (range) serum ferritin concentration for women less than 40 years of age (26.0 
~giL. 14.4-44.7) was significantly lower than for women 40 years or older (38.8 ~giL, 
15.6-74.4), two-tailed p<0.05. However, age and menstrual status were understandably 
highly correlated (r = 0.711) and univariate analyses suggested that menstrual status (R2 = 
0.208, p <0.0001) explained more of the variation in ferritin than age (R2 = 0.105, p 
<0.0001). Multiple regression also revealed that with menstrual status considered a 
priori, the proportion of the variance in serum ferritin explained by regression remained 
the same after adding age to the analysis (R2 = 0.208, p <0.0001). BMI was associated 
with ferritin (r = 0.235), p <0.01 (Figure 5.0), but history of severe bleeding did not 
appear to influence women's serum ferritin concentrations (data not shown). 
Menstruating women showed significantly lower serum ferritin levels than post-
menopausal women or women who had undergone hysterectomy (p<O.OOOl) (Table. 5.2). 
However, there was no association between the amount of menstrual losses, as measured 
by the PBAC, and serum ferritin concentration. 
Mutation status did not influence iron status or menstrual blood loss as measured 
by the PBAC. Ferritin levels in menstruating control women were not significantly 
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different from levels observed in menstruating women who were carriers of the gene that 
underlies mild hemophilia (Table. 5 .2). The P BAC scores of both groups also did not 
differ and there appeared to b e no association b etween women's factor VIII 1 evel and 
PBAC score or iron status (data known shown). Multiple regression analysis utilizing 
PBAC score(~= -:0.046), age(~= 0.063), BMI (~ = 0.267), and Factor VIII(~= -0.193) 
did not appear to have any value with respect to explaining the variation in menstruating 
women's serum ferritin concentrations given the non-significant statistical testing (R2 = 
0.107, p >0.05), although it is likely that other variables that were not considered, such as 
diet and supplement use, could be important in explaining the variation. 
5.3 SF-36 Scores 
Neither the SF-36 domains', health transition scale, nor the two component 
summary measures' mean scores were significantly lower for mildly iron-deficient or 
iron-deficient women. The mean scores for some domains and the physical component 
summary score at select cut-offs were significantly higher for iron-deficient women 
(Table 5.3), however when BMI or age are treated as covariates these differences did not 
reach statistical significance (data not shown). 
5.4 Diagnostic Performance 
The greater the severity of iron deficiency as defined by serum ferritin 
concentration, the higher the probability that the iron deficiency may significantly change 
other laboratory measures such as MCV, RDW and hemoglobin. Table 5.4 shows 
improvement in the sensitivities and the corresponding likelihood ratios of a positive test 
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result at lower serum ferritin cut-offs. As expected, when iron stores are considered fully 
depleted (serum ferritin <11 J.Lg/L) the percentage ofwomen who test positive with MCV, 
RDW and hemoglobin is substantially greater than at higher serum ferritin cut-offs 
(Table 5.4). 
Table 5.0 Characteristics of female and male study participants. 
Characteristic 
Cohort 
Val20 16Ala Mutation 
Control 
Menstruating 
Post-menopausal or hysterectomy 
Females (n = 146) 
84 (57.5%) 
62 (42.5%) 
84 (57.5%) 
59 (40.4%) 
Males (n = 80) 
47 (58.8%) 
33 (41.3%) 
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Age (years) I Range (years) 
BMI 
BMI~30 
45.7 (43.5-48.0)* I 70 
28.0 (25.0-32.0) + 
54.8% (n=68) 
46.1 (43.0-49.2)* I 61 
29.0 (27.0-32.0) + 
45.1% (n=32) 
Hepatitis C 
Diabetes 
Hypertension 
Heart Disease 
Arthritis 
Hysterectomy 
Hemoglobin (giL) 
Serum Ferritin (Jlg/L) 
SF-36 Domains I Components 
0% (n=O) 
10.4% (n=15) 
27.1% (n=39) 
6.3% (n=9) 
19.4% (n=28) 
23.8% (n=34) 
135.5 (131.0-143.0) + 
34.8 (15.6-64.3) + 
17.5% (n=14) 
16.7% (n=13) 
24.4% (n=19) 
14.1% (n=ll) 
19.2% (n=15) 
153.0 (147.0-162.0) + 
156.9 (97.8-262.2) t 
General Health Scale 63.9 (59.9-67.9)* 63.7 (57.6-69.8)* 
Reported Health Transition Scale 2.96 (2.85-3.08)* 3.02 (2.86-3.20)* 
Physical Functioning Scale 80.1 (75.7-84.6)* 81.9 (76.3-87.6)* 
Role Physical Scale 80.4 (75.6-85.2)* 78.0 (71.2-84.8)* 
Role Emotional Scale 89.3 (85.8-92.8)* 93.0 (89.3-96.6)* 
Social Functioning Scale 85.7 (82.0-89.5)* 86.9 (82.3-91.5)* 
Bodily Pain Scale 69.2 (64.7-73.6)* 66.5 (60.5-72.5)* 
Vitality Scale 59.1 (55.8-62.3)* 65.0 (59.3-70.7)* 
Mental Health Scale 75.6 (72.8-78.3)* 79.3 (75.3-83.3)* 
Physical Component Summary Scale 47.7 (45.9-49.4)* 47.0 (44.3-49.7)* 
Mental Component Summary Scale 51.1 (49.7-52.5)* 53.5 (51.5-55.5)* 
Values are expressed as number, mean (95% confidence interval) *, median (interquartile 
range)+, or percentage. 
87 
Table 5.1 Prevalence(%) of suboptimal iron status for women and men sub-grouped by 
menstrual status and mutation status. 
Cohort Serum Ferritin Cut-offTuli/L) 
<50 <40 <20 <11 
Females (n=141) 62.4 55.3 32.6 12.1 
** ** ** * 
Males {n=77) 6.5 6.5 2.6 1.3 
Menstruating Women (n=81) 80.2 71.6 46.9 15.0 
** ** ** 
Non-menstruating Women (n=58) 36.2 31.0 13.8 8.6 
Menstruating Carriers (n=46) 73.9 65.2 57.1 8.7 
Menstruating Controls (n=35) 88.6 80.0 39.1 23.5 
Affected Males (n=46) 6.5 6.5 2.2 0.0 
Control Males (n=31) 6.5 6.5 3.2 3.2 
.. No femtm data for 5 females and 3 males; menstrual status unknown for 2 women. 
**Pchi-Square < 0.0001 
*PChi-Square < 0.01 
Table 5.2 Median serum ferritin concentrations for females and males grouped by 
menstrual status and cohort 
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Cohort Median (Interquartile Range) Serum Two-tailed 
Ferritin Concentration (J.lgiL) p-value 
Females (n=141) 34.8 (15.6-64.3) P<O.OOl 
Males (n=77) 156.9 (97.8-262.2) 
Menstruating Women (n=81) 22.1 (13.8-44.1) p <0.001 
Non-menstruating Women (n=58) 62.6 (36.8-112.6) 
Menstruating Carriers (n=46) 24.2 (14.7-54.4) p >0.05 
Menstruating Controls (n=35) 18.7 (11.3-32.5) 
Affected Males (n=46) 135.3 (94.5-237.1) p >0.05 
Control Males (n=31) 238.2 (104.3-301.5) 
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r = 0.235, p <0.01 
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Figure 5.0 Scatter plot of serum ferritin concentration {J!g/L) vs. BMI. 
Table 5.3 Mean (95% confidence interval) scores on the eight domains, health transition scale and two component summary scores of the SF-36 for 
women of different iron status as defined by various serum ferritin cut-offs. 
Iron status: Women's mean (95% confidence interval) scores on the eight domains and two component summary scores of the SF-36 
serum ferritin 
cone. (J.lg/L) GHS HTS PFS RPS RES SFS BPS VTS MHS PCS 
<50 68.0 2.91 83.9 79.9 91.6 85.6 72.4 61.3 76.5 48.9 
(63.7-72.4) (2.78-3.05) (78.4-89.3) (73.4-86.5) (87 .3-95.8) (80.8-90.5) (66.8-78.1) (57.8-64.9) (73.1-79.9) (46.7-51.2) 
• 
~50 57.8 3.00 75.7 82.0 87.2 87.3 64.2 56.3 75.3 45.8 
(50.1-65.5) (2.79-3.21) (67.9-83.5) (74.4-89.6) (81.0-93.4) (81.2-93.3) (56.7-64.8) (49.9-62.6) (70.7-79.9) (42.7-48.8) 
<40 68.5 2.92 84.9 79.7 91.4 85.7 73.9 60.6 76.3 49.5 
(63.9-73.0) (2.77-3.07) (79.3-90.6) (72.5-87.0) (86.7-96.2) (80.3-91.1) (68.3-79.6) (56.7-64.4) (72.7-79.9) (47.2-51.8) 
• • • • 
~40 59.1 2.98 75.8 81.9 88.1 86.9 63.8 58.0 75.8 45.7 
(52.4-65.9) (2.80-3.17) (68.7-83.0) (75.1-88.6) (82.8-93.4) (81.6-92.2) (56.7-70.9) (52.4-63.6) (71.5-80.0) (42.9-48.6) 
<20 68.4 2.96 85.8 85.1 91.3 85.5 75.6 61.8 74.1 50.7 
(62.8-74.0) (2.80-3.11) (78.6-93.0) (77 .6-92.5) (85.7-96.9) (78.4-92.6) (68.9-82.2) (56.9-66.7) (69.3-78.9) (48.2-53.2) 
• • 
~20 61.9 2.94 78.1 78.5 89.1 86.6 66.0 58.1 77.0 46.2 
( 56.5-67.3) (2.78-3.10) (72.4-83.8) (72.1-85.0) (84.6-93.7) (82.2-91.1) ( 60.2-71.9) (53.9-62.4) (73.7-80.4) (43.8-48.6) 
<11 68.9 2.94 77.5 79.7 89.6 80.5 68.4 57.4 70.9 48.1 
(58.8-78.9) (2.60-3.28) (61.2-93.8) (63.5-95.9) (79.1-100.0) (65.3-95.7) (55.8-81.0) (50.2-64.5) (62.6-79.2) ( 43.0-53.1) 
~11 63.3 2.95 81.0 80.7 89.8 86.9 69.2 59.5 76.7 47.6 
(58.9-67.7) (2.82-3.07) (76.3-85.7) (75.4-86.0) (86.0-93.6) (83 .1-90.8) (64.3-74.1) (55.8-63.1) (73.8-79.6) (45.7-49.6) 
*p <0.05, two-tatled 
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MCS 
51.5 
(49.8-53.3) 
51.1 
(48.5-53.7) 
51.3 
(49.4-53.2) 
51.5 
(49.3-53.7) 
50.4 
(47.7-53.0) 
51.9 
(50.2-53.6) 
49.6 
(44.2-54.9) 
51.4 
(50.1-53.0) 
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Table 5.4 Sensitivities, specificities, and likelihood ratios for mean cell volume (MCV) <80 fL, 
red cell distribution width (RDW) >14.5, and hemoglobin (Hb) <120 giL as diagnostic tests of 
sub-optimal iron status defined by women's serum ferritin concentrations. 
Serum Ferritin Test Sensitivity Specificity Likelihood Ratio 
Cut-off (%) (%) Positive Test Result Negative Test Result 
<50 Jlg/L MCV 4.5 98.1 2.37 0.97 
RDW 12.5 86.8 0.95 1.01 
Hb 5.7 98.1 3.00 0.96 
<40 Jlg!L MCV 5.1 98.4 3.19 0.96 
RDW 12.8 87.3 1.01 1.00 
Hb 6.4 98.4 4.00 0.95 
<20 JlgiL MCV 8.7 98.9 7.91 0.92 
RDW 17.4 89.5 1.66 0.92 
Hb 10.9 98.9 9.91 0.90 
<11 Jlg/L MCV 23.5 99.2 29.4 0.77 
RDW 23.5 88.6 2.06 0.86 
Hb 29.4 99.2 36.8 0.71 
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6.0 Iron Deficiency in Women 
Iron deficiency is prevalent m women residing in rural Newfoundland, 
particularly in menstruating women. While the population studied is not representative of 
the general population because of the high prevalence of carrier status for mild 
hemophilia A, the prevalence of iron deficiency in the women studied is similar to that of 
two other Canadian studies. Valberg et al. found 27% of non-pregnant women aged 20-39 
(n=lOO) and 24% of non-pregnant women aged 40-64 (n=105) had serum ferritin results 
<15J.Lg/L (Valberg, Sorbie, Ludwig, & Pelletier, 1976). Using a cut-off of <l5J.Lg/L, we 
observed a prevalence of 26% in women less than 40 years of age and a prevalence of 
21% in women 40 years and older. Newhouse et al. observed iron deficiency, measured 
by serum ferritin levels <20J.Lg/L, in 39% of 111 women aged 18-40 residing in Thunder 
Bay Ontario (Newhouse, Clement, & Lai, 1993). Using a cut-off of <20J.Lg/L, we 
observed a prevalence of 41% in women less than 40 years of age. We used a range of 
cut-off values for diagnosing sub-optimal iron status in both women and men. The 
validity of using a lower, gender-specific serum ferritin value for women has been 
questioned (Rushton, Dover, Sainsbury, Norris, Gilkes, & Ramsay, 2001). Laboratories, 
with different methods of measuring serum ferritin, establish their own reference range 
based on reference values from a healthy sample of the population. These reference 
values may in fact be taken from women who have a suboptimal level of storage iron; 
that is, their iron stores are not necessarily empty, but are mildly depleted. 
Evidence suggests that the effects of mild iron deficiency on cognition and fatigue 
may be evident before anemia or even before iron store depletion. Indeed, Verdon et a!. 
showed a significant improvement in fatigue after iron supplementation in women with a 
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baseline serum ferritin concentration < 50 Jlg/L (Verdon et al., 2003). Several well-
designed studies, of women and adolescent girls, have shown that there iron deficiency 
without anemia is related to impaired cognition, fatigue and physical activity (Bruner et 
al., 1996; Rowland et al., 1988; Verdon et al., 2003). Possible casual mechanisms by 
which iron may effect behavioural and cognitive changes that have been observed in iron 
deficiency are believed to be associated with a decreased activity of iron-containing 
enzymes in the brain and possibly independent of hemoglobin synthesis. Animal models 
have suggested that the neurophysiological underpinnings of the behavioural and 
cognitive changes observed during iron deficiency may be the impairment of iron-
dependent enzymes activity necessary for the synthesis, function, and degradation of 
neurotransmitters, such as dopamine, serotonin and, norepinephrine (Dallman, 1986). 
Similarly, one clinical study suggested that body iron stores are relevant to specific 
neurophysiological processes supporting attention (Tucker et al., 1984). 
Deficits observed in mildly iron-deficient individuals and the debate surrounding 
what constitutes a "normal" physiological reference range in women suggest that lower 
values used by laboratories to establish reference ranges for women may actually be 
abnormally low. Using a more moderate cut-off of serum ferritin < 40 Jlg/L, the 
prevalence of iron deficiency in our population was 71.6% for menstruating women and 
55.3% in all women. Further studies on the clinical impact of iron depletion are required 
to determine whether such high percentages call for an investigation into identifying 
areas of intervention, necessary for the development and implementation of strategies 
aimed at repleting this cohort. There is growing evidence that in some settings lower iron 
stores may have physiological advantages - namely, decreased risk of atherosclerosis, 
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myocardial infarction, and ischemic stroke (Tumainen, Salonen, Nyyssonen, & Salonen, 
2003; K.iechi, Willeit, Egger, Poewe, & Oberhollenzer, 1997; Sullivan, 1989). A 
potential for iron overload in some people also exists if iron supplementation is broadly 
applied, as the population will include patients carrying one or more copies of mutated 
genes responsible for hemachromatosis, a disorder of iron overload due to over-
absorption of iron from the diet. The gene mutations responsible for hereditary 
hemochromatosis are most prevalent among persons of European origin and descent, with 
a reported C282Y heterozygosity of 9.2% and a H63D carrier frequency of 22%. In 
populations with European origin or descent, the prevalence estimate for C282Y 
homozygosity is 0.4% and it is estimated that 40-70% of persons with this homozygous 
genotype will develop clinical evidence of iron overload (Hanson, lmperatore, and Burke, 
2001). 
Likewise, a comprehensive literature search on the prevalence of celiac disease in 
western European populations listed the prevalence of celiac disease in pre-menopausal 
women with iron deficiency anemia to be 8.5% after biopsy examination confirmation 
and the prevalence in general Western populations as being close to 1 % ( Dube e t al., 
2005). Celiac disease is a chronic nutritional disturbance caused by the inability to 
metabolize gluten, which may result in inadequate absorption and malnutrition. These 
considerations create uncertainty as to whether an intervention to iron replete a group 
such as this cohort will do more good than harm. Large simple clinical trials or 
population-based cohort studies would be warranted before a policy of routinely 
increasing the iron intake of a population could be justified. 
96 
Studies of iron repletion and/or food fortification have supported increasing the 
iron intake of non-anemic menstruating women with ferritin levels ranging from <12 to 
<50 Jlg/L. Experimental studies using iron supplementation demonstrated improved 
verbal learning and memory in non-anemic adolescent girls (Bruner et al., 1996), showed 
improved exercise capacity and physical performance in menstruating adult women 
(Brutsaert et al., 2003; Rowland et al., 1988), and benefited women of reproductive age 
with unexplained fatigue in the absence of anemia (Verdon et al., 2003). A large non-
experimental cross-sectional cohort study, using baseline and follow-up data from the 
first two years of the Australian Longitudinal Study on Women's Health (ALSWH), also 
found an association between self-reported iron deficiency and general health and well-
being, vitality and fatigue in Australian Women. (Patterson et al., 2000). In follow-up to 
the associations observed in the A LSWH study, the effects of iron deficiency without 
anemia on general health, well-being, and tiredness was systemically investigated in a 
randomized controlled clinical trial. Treatment of iron deficiency with either 
supplementation or a high iron diet resulted in improved mental health and decreased 
fatigue among menstruating women (Patterson et al., 2001). 
Menstruation h as b een c onsistently i dentified as the m ain c ause o f i ron 1 oss i n 
women and evidence suggests that women may not be adequately repleting their iron 
stores. The Report of a Survey of Residents of Newfoundland and Labrador, 1996, 
suggested that although the iron intakes of males and senior females appeared adequate, 
many females less than 50 years appeared to be consuming an inadequate amount of iron. 
The survey showed that 25.3% of females aged 19-30 and 33.3% of females aged 31-49 
were consuming less than the Estimated Average Requirement (EAR) (Roebothan, 2003). 
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Most of the variation in serum ferritin concentrations in the present study was due to 
other factors that were not considered, such as supplement use, inadequate dietary intake 
of iron and insufficient iron absorption. Further research is required to determine whether 
the low ferritin levels observed in women could possibly be due to these factors and 
whether such levels have a negative clinical impact. 
6.1 Iron Deficiency and Quality of Life 
Neither the means of the eight SF-36 domains, health transition scale, nor the two 
component summary measures were significantly lower for mildly iron-depleted or iron-
deficient women. The sample sizes in our groups were large enough to detect the 5-point 
difference required for a clinically and socially relevant difference between the group 
means. In fact positive correlates of iron depletion were shown for the General Health 
Scale, Physical Functioning Scale, Bodily Pain Scale, and the Physical Component 
Summary Score. However, treating BMI and Age as covariates eliminated these 
differences, suggesting that they were likely the result of the confounding by correlations 
observed between serum ferritin concentration with both BMI and age. It is also possible 
that these differences may reflect physiological advantages of having low body iron 
stores, but this would have to be tested with further study. 
The SF-36 is also a general measure of various quality of life domains and may 
not have been sensitive enough to measure the effects iron deficiency potentially had on 
women's cognition and fatigue. This study was undertaken as an ad hoc component of a 2 
year cross-sectional study aimed at defining the clinical impact of mild hemophilia A and 
therefore, existing instruments that directly measure cognition and fatigue were not 
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utilized. A study using a disease specific instrument, more sensitive to these effects, 
would better investigate the impact of iron deficiency or iron depletion. 
6.2 Iron Deficiency and Mild Hemophilia A 
Mutation status did not influence iron status in either sex. Mutation status also had 
no effect on menstrual blood loss as measured by the PBAC, nor was factor VIII level 
associated with PBAC score. It appears that the factor VIII levels observed in the women 
carriers of mild hemophilia A did not put them at risk for experiencing menorrhagia or 
iron deficiency. 
PBAC score also did not appear to be associated with iron status. The PBAC may 
not have been sensitive enough to detect the difference in blood 1 oss between women 
with low and normal ferritin levels. Pads and tampons were not provided for the study 
participants. Providing specific sanitary protection may have better controlled for the 
varying absorptive capacity oft he wide variety of products that are available. Even if 
specific sanitary protection is provided, there may not be an accurate and reliable method 
for assessing menstrual blood loss other than the alkaline hematin method. There is 
generally poor correlation between menstrual blood loss and patients' subjective 
assessment of blood loss and other parameters applicable to the menstrual cycle (number 
of days of bleeding, number of sanitary pads and tampons used) (Chimbira, Anderson, & 
Turnbull, 1980) and it appears that this study may have shown the same result despite the 
usage of a pictorial guide. However, to be certain we would have had to measure the 
PBAC against the alkaline hematin method. 
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The literature validating the PBAC against the alkaline hematin method is not 
consistent. Reid et al. showed poor correlation between observed PBAC score and 
menstrual blood loss as measured by the alkaline hematin method and dismiss the PBAC 
method as unable to accurately assess menstrual blood loss (Reid et al., 2000). Studies 
also suggest different cut-offs for diagnosing menorrhagia. We choose a PBAC score of :s 
100 to diagnose menorrhagia as this was the cut-off used by Kadir et al. (1999) to 
demonstrate menorrhagia in 57% of hemophilia AlB carriers, in comparison to only 29% 
for control women (p=0.001) (Kadir et al., 1999). 
As previously mentioned, we found no association between mutation status and 
menstrual blood loss as measured by the PBAC. Rather than the PBAC simply being an 
invalid measure, it is possible that mild hemophilia carriers are not at risk for excessive 
menstrual bleeding and that the differences observed by Kadir et al. were an overestimate 
resulting from a poor response rate (26%) from these carriers. The low rate possibly 
being due to the fact that they suffer fewer problems compared to the women with other 
mild bleeding disorders (vWD response rate, 69%; FXI, 47%; Control, 60%) (Kadir et 
al., 1999). 
6.3 Future Directions 
The prevalence of iron depletion in rural Newfoundland is high. Further research 
is required to determine whether the low ferritin levels observed in women could possibly 
be a result of inadequate dietary intake of iron or insufficient iron absorption. We were 
unable to show that carriers of the gene responsible for mild hemophilia A in our study 
population experience more menstrual blood loss than controls. Nor could we show that 
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the former have lower iron stores. Using the alkaline hematin method to measure 
menstrual blood loss and measuring iron consumption and absorption could make more 
accurate and reliable comparisons on these fields. Furthermore, whether such levels have 
a clinical effect harmful enough to suggest that a repletion intervention would do more 
good than harm also warrants further study. Neither iron depletion nor iron deficiency 
appeared to negatively affect quality of life as measured by the SF-36 questionnaire. A 
study using measures to investigate the potential effects iron depletion and iron 
deficiency have on cognition and fatigue could more specifically explore its negative 
impact. 
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Appendix A: MOS short-form survey (SF-36) 
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Your Health and Well-Being 
This survey asks for your views about your health. This information will help 
keep track of bow you feel and how well you are able to do your usual activities. 
Thank you for completing this s11rvey! 
For eacb of the foUowing questions, please mark au ~ in the one box that best 
describes your answer. 
I. In general, would you say your health is: 
Excellent Very good 
'Y 'Y 
o. 0: 
Fair 
T 
o .. 
Poor 
'Y 
D· 
l. Compared to one year ago, bow would you rate your health in general 
nm? 
Somewhat Somewhat 
Mudlbetter better About the worse Much worse 
now than one nowtbanone sameu now than one now than one 
year ago year ago one year ago year ago year ago 
y y T T 'Y 
D· o, o, o~ o, 
SF..JMN Hcaldl SiW'¥cy'C ml.:octl1tly Baldi•'" mt LJIIt. Medical~ T.,.. _.QI&IIilyMdrirt ~ All ripe. _..a. 
Sl'·l6alila~.,.,._..,...~~T-. 
3. The following questions arc about activities you might do during a typical 
day. Does vour health now limit you in these activities? If so, how much? 
' 
Yes. 
limited 
a lot 
• 
Yes. 
limited 
a little 
• 
No, not 
limited 
at all 
• Vigorous acJjyiries. sucb as running. lifting 
heavy objects, panicipacing in strenuous sports. ................... 0 • ............ 0 : ............. 0 J 
Moderate actMties. such as moving a cable. pushing 
a vacuum cleaner. bowling. or playing golf .......................... 0 ' ............ 0 ' ............. 0 J 
Lifting or carrying groceries ................................................ 0 • ............ 0 : ............. 0 } 
Climbing ~ Bights of stairs .......................................... 0 • ............ 0 : .. ........... 0 • 
Climbing~ flight or stairs ................................................. 0 I ............ 0 : ............. o ) 
Bending. kneeling. or stooping ............................................ 0 • ............ 0 : ............. 0 , 
Walking more than a kUometre ............................................ 0 a ............ 0 1 ............. 0 1 
Walking several bundrClJ nu;tn;s .......................................... 0 I ............ 0 l ............. o ) 
Walking one hundred metres ............................................... 0 , ............ 0 : ............. 0 , 
Bathing or dressing yourself ................................................ 0 1, ........... 0 l ............. o ) 
4. Durina the past 4 weeks, how much of the time have you had any of the 
followiua problems with your work or other replar daily activities!!.!! 
result of your nhysiql health? 
Cut down on the amount of 
limA you spent on work or 
All of' 
the time 
.. 
Most of 
the time 
.. 
Some or 
the time 
.. 
A little of None of 
lhc time the time 
. .. 
other activities. ............................. 0 ' ............. 0 t ............. 0 ) ............. 0 .............. 0 ' 
" Accompljsbed 1m tban you 
\VOuld like .................................... 0 .............. 0 : ............. 0 ) ............. 0 .............. 0 l 
Were limited in the kind of 
work or other activities ................ 0 .............. 0 : ............. 0 ) ............. 0 ~ ............. 0 • 
.s Had difficuky perfonning the 
the work or other activities (for 
exampl~ it took extra cffon) ........ 0 1 ............. 0 2 ............. 0 ,, ............ D .............. 0 ' 
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S. During the past 4 wee~ how much of the time have you bad any of the 
foUowiog problems with your work or other replar daily activities as a 
result of any emotioaal problems (such as feeling depressed or anxious)? 
AU of 
tbetimc 
... 
Most of Some of A little of None of 
the time the time the time the lime 
............ 
Cut down on tbe IOOOUDl Q( 
time you spent on work or 
other activities. ............................. 0 ' ............ 0 : ............. 0 '········ .... 0 ·············· 0 ~ 
Acc<>mplisbed less than you 
would like .................................... 0 1 ............. 0 :. ............ 0 ) ............. 0 ~ ............. D ~ 
Did work or other ae1ivities 
less carefiJIIy than usual ................ 0 .............. 0 : ............. 0 , ............. 0 .............. D · 
6. During tbe oast 4 week5. to what extent has your physical health or 
emotional problems iaterfered with your normal social activities with 
family, friends, neighbors, or groups? 
Not at all Quite a bit 
... • o~ 
7. How much bodily paiD have you had duriDg the past 4 weeks? 
None Very mild Mild Moderate Severe Very severe I 
... ... ... ... ... ... 
01 o, o, o~ o~ o. 
113 
8. During the past 4 weeks, how much did pain interfere with your normal 
work (including both work outside the home and housework)? 
Not at all A little bit Moderately Quite a bil Extremely 
... ... ... ... ... 
01 0: D" o~ o~ 
9. These questions are about how you feel and how things have been with you 
during the past 4 weeks. For each question, please give the one answer that 
comes closest to the way you have been feeling. How much of the time 
during tbe past 4 weeks ... 
All of 
the time 
... 
MostoC 
the time 
... 
Some of 
the time 
... 
A little o( 
the time 
.... 
None of 
the time 
... 
• Did you feci fuD Oflif'e? •••••••••••••••• 0 I .......••.... 0: ............. 0 ) ............. o '············· 0 ~ 
• Have you been vety nctVOUS? ••••••• 0 • ............. 0 2 ••••••••••••• 0 , ............. 0 .............. 0' 
, Have you felt so down in the 
dumps that nothing could 
cheer you up? ••••••••••••••••••••••••••••••• 0 I ............. o l ............. o ), ............ o •••••·····•••• 0 ' 
4 Have you felt calm and 
peacefi.d? ...................................... o, ............. o : ............. o ............... o ~ ............. o. 
• Did you have a lot of enersy? ••••••• 0 s ··-·-·---.0 2. ............ 0 ........... -.. 0 • ............. 0' 
r Have you felt downhearted 
and depressed? ............................. o .............. o J ............. o .............. o .............. o. 
• Did YOU fed worn OUt? ................. 0 I •••••••••••••0 l ......... , ..• o ) ............. 0 .............. 0' 
.. .~::~ave you been happy? .................. o ............. .o l ............. o .............. o ~ ............. o , 
• Did you feel tired?··----···--·-···--··· 0 , ............ .0 ~ ............. 0 :~ ............. 0 .............. 0 , 
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10. During the past 4 weeks, how much of the time has your physical health 
or emotional problems iDterfcred with your social activities (like visiting 
witb friends, relatives, etc.)? 
All of 
the time 
Most of 
&he time 
'Y 
Ot 
Some of 
the time 
'Y 
o, 
A tittle of 
the time 
'Y 
None of 
the time 
'Y 
D· 
1 J. How TRUE or FALSE is each of the following statements for you? 
Definitely Mostly 
true true 
... 'Y 
Oon•t 
know 
... 
Mostly Oefinitdy 
false false 
... ... 
• I seem co get side a little 
ea.sier tllln. other people ... ._ ............ 0 • .............. 0 :a .............. -0 ., ................ 0 -~. .. -........... D ' 
~ t am u healthy as 
anybody I know ........................... 0 , ............. 0 : ............. 0 , ............. 0 .............. D' 
(expect my health to 
set \Verse ..................................... D 1 ............. 0 : ............. 0 l ............. 0 ~ ............ D; 
' My health is excellent ................... D 1 ............. 0 , ............. 0 J ............. o .............. 0 J 
Tlzank you for completing these questions! 
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How to Use the Pictorial Blood Asscumaat Chart 
McnoCTbagia is defmcd as heavy, prolonged bleeding throughout the menstrual cycle. 
This can impac:c a woman's daily life causing disruptions in work and daily activities. W c 
arc using this 3.SSC$$1DCDt cbart co pin a bcctcr UDdcrslaDding and rate of 
mcnonbagia.Pleasc complete the foJlowing questionnaire during your next mcnsaual 
period. In order to assure reliable results. we would ask you co trade the infonnation 
concerning your menstrual period on :a daily basis in the tables dw follow, for eadl 
tampoll or pad U$Cd. 
How to: E2dl/ represents one pad or tAmpon utecL For each day your period lasts 
check ofl' a (I) lndlcatinc the numbn and description or the tampon or pad used. 
For example, U' on day 1 you bave used 2 Ugbtly soaked pads and nothlna else you 
would write In //In the appropriate box or on dayS you used 2 Ugbtly soaked p:uls 
and one U&htly soaked tAmpon you mark //in the COrTC$pondlug box tor pads and I 
in the corrc:spondinc bo:~ for tampons. •see mustratlon below. 
OATE 
-f1 .J's 
. 
TOWEL 2 3 4 6 7 8 
u I 
' 
II I 
im Ill II 
ll n 
TAMPON ,.1 2" 3 4 ~ a 7 8 
-
. ,.. I I 
-
~ II l1l II 
A. WI Ill 
Pleuc iadicate which brand of pads you u.se=--~~--------­
Plcasc chcdc the word that best describes the type of pad: 
Light Rcplar Heavy E.xn heavy 
Please iadicalc whicb brand of tampons you use: ______________ _ 
Please check Chc wont tbal best describes the type of pad: 
Li&ht R.eplar Heavy Extra heavy 
Once you bave completed this questionnaire please mail it back co us in the self-addressed 
envelope supplied. You may be conucled by study personnel as a mcndty reminder. 
Please do not hesitate to concacl us with any question.s. You can reach Mcgban at 777· 
SS36 or David at 717·7530. Tluz11k you t~gt~lnfo, ptUtic/ptJtlng hi t1U' #Udy!! 
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DAYS 1 2 3 
" 
s 6 1 a 
' 
10 11 u 
DAm 
PADS 
U&btly soaked 
~ 
Moderately soaked 
<:!!) 
Heavily soabd 
.. 
TAMPONS 
--n 
-~ 
Heavily soaked 
I 
Oocs 
tcm or less 
Clots 
More chan tcm 
Bloocllowins 
oucskle the pacl 
«tampon 
Tocal number of clays o( menmual period:-----
2 
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Personal Interview Questionnaire 
Thank you for participating in our study. The purpose of this questionnaire is to get a 
general picture of our participants. Personal identifiers such as you name and phone 
number is requested only to confirm some questions we may have following your 
participation or to fill-in missing information. Once this information is gathered these 
identifiers will be removed before being entered in our database as outlined in the 
consent form. 
General Information 
Name: ___________________ _ Date (yy/mm/dd): _____ _ 
Mailing Address: ---------------------------------
Date of birth (yy/mm/dd): -------- Age: _____ _ 
Family Physician:------------
Personal Health History 
• Have you ever been diagnosed with a bleeding disorder or had an abnormal loss 
of blood making it necessary to consult with a doctor following an injury? 
YesO No 0 If yes: 
How old were you? _____ __ 
What was the problem?-------------------------
What was the treatment? ______________________ _ 
• Are you presently receiving care for a bleeding disorder? 
Yes 0 No 0 If yes: 
What treatment are you receiving?---------------------
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• Have you been diagnosed with any other medical disorders or problems? 
Yes Cl No Cl lfyes: 
Please check off any of the following that apply: 
Diabetes 0 
Hypertension (high blood pressure) 0 
Heart disease D 
Arthritis 0 
Other: __________________________________________________ _ 
• Do you take medication on a regular basis? 
Yes Cl No 0 If yes: 
List the names of the medication you have taken in the last month: 
Bleeding History 
• Do you have a tendency to bruise easily? 
Not at all 0 Very little D A bit D AlotD Very much D 
• Do you bleed from your gums when you brush your teeth? 
Not at all D Very little 0 A bit 0 A lot 0 VerymuchO 
• Do you have a tendency to have nosebleeds for no apparent reason? 
Not at all 0 Very little D A bit D A lot D Very much D 
• Have you ever had an abnonnalloss of blood from an injury, dental work or 
surgery? 
YesO No 0 If yes: 
How old were you? __ _ 
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What was the problem?--------------------
What was the treatment?--------------------
• Did you ever receive a blood transfusion or blood product due to an abnormal loss 
of blood? 
Yes 0 No 0 Ifyes: 
How old were you? _____ _ 
Was it more than once? Yes 0 No 0 
What was the treatment?--------------------
Gynecological History 
• How old were you when your menstrual periods began? ___ _ 
Typically, how many days do they last?---------
In how many days does your menstrual cycle reoccur? ___ _ 
• Do you bleed between your menstrual periods? 
Yes 0 No 0 lfyes: 
Very rarely 0 Rarely 0 Often 0 Very Often 0 Always 0 
• Do you have clots during your menstruation? 
Yes 0 No 0 lfyes: 
Very rarely 0 Rarely 0 Often 0 Very Often 0 Always 0 
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• Do you stain your clothing during your menstruation? 
Yes D No D lfyes: 
Very rarely D Rarely D Often D Very Often D Always D 
• Do you stain your bed during your menstruation? 
Very rarely D Rarely D Often D Very Often D Always D 
• Do you have pain during your menstruation? 
Not at all Cl Very little Cl A bit Cl A lot Cl Very much Cl 
• Do you take medicine to ease your menstrual pain? 
Never Cl Rarely Cl Often Cl Very Often Cl Always Cl 
• Have you ever had to consult a doctor because of abnormal menstrual periods? 
YesD NoD If yes: 
What was the treatment?--------------------
• Do you sometimes miss school or work because of your menstruation? 
Yes D No Cl If yes: How many days? ___ _ 
• Does your menstrual period interfere with your social life? 
Not at all D Very little D A bit D A lot D Very much D 
• Does your menstrual period interfere with your sex life? 
Not at all Cl Very little Cl A bit Cl A lot Cl Very much Cl 
• Have you ever taken contraceptives (the Pill)? 
Yes D NoD lfyes: 
For contraception D 
To regularize your cycle D 
To diminish your bleeding D 
• Did the contraceptives: 
Increase your menstrual period C1 
Diminish your menstrual period C1 
Change nothing in your menstrual period C1 
Obstetrical History 
• Have you ever tried to get pregnant? 
Yes C1 No C1 
• How many times have you been pregnant? __ _ 
• In general, for the majority of your pregnancies, how much time passed, on 
average, between the time you decided o get pregnant and the moment you 
became pregnant? 
Less than 3 months C1 
Between 3 and 6 months C1 
Between 6 and 12 months C1 
More than 12 months C1 
• Have you had any miscarriages or stillbirths? 
Yes C1 No C1 If yes: 
How many miscarriages? ___ _ Stillbirths? ___ _ 
• How many times have you given birth? ___ _ 
Vaginal birth: ____ _ 
Caesarean section: ___ _ 
• Did your doctor tell you that you bled abnormally after one or more of your 
childbirths? 
Yes C1 No C1 If yes, how many? 
Vaginal births ___ Cesarean section ___ _ 
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• Have you needed a blood transfusion for a hemorrhage associated with childbirth? 
YesO No 0 
• Have you had a hysterectomy? Yes 0 No 0 If yes, at what age? __ _ 
What was the reason? 
--------------------------------------------
Were you treated for excessive bleeding after the procedure? ---------------
Family History 
• Do you have brothers? YesO NoD 
Do you have sisters? Yes D No D If yes: 
How many living brothers do you have? ____ _ 
How many living sister do you have? _____ _ 
Have you ever lost a brother or sister because of bleeding? 
YesD NoD 
Details: -------------------------------------
• Do you have sisters with abnormal periods? 
Yes 0 No 0 Don't know D If yes: 
How many? ______ _ 
Is there an illness known to explain their abnormal menstrual periods? ___ __ 
• Does/Did your mother have a history of abnormal menstrual periods? 
Yes D No 0 Don't know D 
Is/Was there an illness known to explain their abnormal menstrual periods? __ 
• Do you know of other women in you family who have had hysterectomy due to 
heavy bleeding? Yes D No D If yes, please list relationship to you._ 
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• Do you have someone in your immediate or close family who is known to have a 
hereditary (from birth) hemorrhagic problem? 
Yes 0 No 0 Don't know 0 If yes: 
What is your relation to this person?----------------
What is the name of the hereditary hemorrhagic problem? _______ _ 
• Do you have someone in your immediate or close family who has had any of the 
following problems? Yes 0 No 0 Don't know 0 
If yes, please check those that apply: 
Nosebleeds 0 Bleeding after surgery 0 
Bleeding with dental work 0 Easy bruising 0 
Thank you for participating in our study! 




